

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
4 January 2007 (04.01.2007)

PCT

(10) International Publication Number
WO 2007/002762 A2

(51) International Patent Classification:
C12N 5/04 (2006.01)

(21) International Application Number:
PCT/US2006/025195

(22) International Filing Date: 27 June 2006 (27.06.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/694,236 28 June 2005 (28.06.2005) US

(71) Applicant (for all designated States except US): **VENTRIA BIOSCIENCE** [US/US]; 4110 N. Freeway Boulevard, Sacramento, CA 95834 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **DEETER, Scott** [US/US]; 4207 Harbour Walk Drive, Fort Collins, CO 80525 (US). **SCHMIDT, Joseph, E.** [US/US]; 2009 Renoir Avenue, Davis, CA 95616 (US). **MABERY, Kenneth, J.** [US/US]; 3136 Glentana Way, Antelope, CA 95843 (US). **BETHELL, Delia, R.** [US/US]; 390 C Street, West Sacramento, CA 95605 (US). **HUANG, Ning** [CN/US]; 1226 Caricia Drive, Davis, CA 95616 (US).

(74) Agents: **BERMAN, Richard, J.** et al.; Arent Fox PLLC, 1050 Connecticut Avenue, N.W., Suite 400, Washington, DC 20036 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMPONENTS OF CELL CULTURE MEDIA PRODUCED FROM PLANT CELLS

(57) Abstract: The present invention comprises the production of components of cell culture media produced from plant cells and cell culture media containing the same. Heterologous DNA comprising genes encoding the desired component are introduced into plant cells, especially rice, which then produce the desired component. The component can be isolated from the plant cell and combined with other components to form the required cell culture medium.

Components of Cell Culture Media Produced from Plant Cells

[0001] This application claims priority benefit to U.S. provisional application Serial No. 60/694,236 filed June 28, 2006. The priority application is incorporated herein by reference in its entirety.

1. Field of the Invention:

[0002] The present invention relates to the production and use of recombinant proteins produced by plant cells as components of cell culture media.

2. Background of the Invention:

[0003] Cell culture techniques allow animal or plant cells that are removed from tissues to grow when supplied with the appropriate nutrients and conditions. The cells are capable of dividing and can continue to grow until limited by some culture variables such as nutrient depletion or toxic buildup (Butler, M. & Jenkins, H., Nutritional aspects of growth of animal cells in culture, *J of Biotechnol.* (1989) 12: 97-110). Cell culture techniques have a number of applications including investigation of the normal physiology or biochemistry of cells (Balaban, B. & Urman, B., Embryo culture as a diagnostic tool, *Reprod. Biomed. Online* (2003) 7(6): 671-82), testing the effect of various chemical compounds or drugs on specific cell types (Farkas, D. & Tannenbaum, S.R., In vitro methods to study chemically-induced hepatotoxicity: a literature review, *Curr. Drug Metab.* (2005) 6(2): 111-25), studying the sequential or parallel combination of various cell types to generate artificial tissues (Wang et al., Cartilage tissue engineering with silk scaffolds and human articular chondrocytes, *Biomaterials* (2006)), and synthesizing valuable biologics from large scale cell cultures (Zeilinger et al., Three-dimensional co-culture of primary human liver cells in bioreactors for in vitro drug studies: effects of the initial cell quality on the long-term maintenance of hepatocyte-specific functions, *Altern. Lab Anim.* (2002) 30(5): 525-38). Cell culture techniques have also been used for in vitro fertilization (Blake et al., Protein supplementation of human IVF culture media, *J Assist. Reprod. Genet.* (2002) 19(3): 137-43; Bungum et al., Recombinant human albumin as protein source in culture media used for IVF: a prospective randomized study, *Reprod. Biomed. Online* (2002) 4(3): 233-6), stem cell research (Conley et al., Derivation, propagation and differentiation of human embryonic stem cells, *Int. J Biochem. Cell Biol.* (2004) 36(4): 555-67), vaccine production (Chuang

et al., Pharmaceutical strategies utilizing recombinant human serum albumin, *Pharm. Res.* (2002) 19(5): 569-77; GlaxoSmithKline, Publisher. HAVRIX® (Hepatitis A Vaccine, Inactivated) - Prescribing Information (2005), available at http://us.gsk.com/products/assets/us_havrix.pdf; Innis et al., Protection against hepatitis A by an inactivated vaccine, *JAMA* (1994) 271(17): 1328-34; Merck, Publisher. PROQUAD® - Measles, Mumps, Rubella, and Varicella (Oka/Merck) Virus Vaccine Live - Prescribing Information (2005), available at http://www.merck.com/product/usa/pi_circulars/p/proquad/proquad_pi.pdf; Litwin, J., The growth of Vero cells in suspension as cell-aggregates in serum-free media, *Cytotechnology* (1992) 10(2): 169-74), tissue engineering including artificial skin (Atala, A., Future perspectives in reconstructive surgery using tissue engineering, *Urol. Clin. North Am.* (1999) 26(1): 157-65, ix-x; Sher, et al., Targeting perlecan in human keratinocytes reveals novel roles for perlecan in epidermal formation, *J Biol. Chem.* (2006) 281(8): 5178-87) and organs (Neronov et al., Integrity of endothelium in cryopreserved human cornea, *Cryo Letters* (2005) 26(2): 131-6; Han, et al., Interleukin-1alpha-induced proteolytic activation of metalloproteinase-9 by human skin, *Surgery* (2005) 138(5): 932-9) and gene and cell therapy (Chadd, H.E. & Chamow, S.M., Therapeutic antibody expression technology, *Curr. Opin. Biotechnol.* (2001) 12(2): 188-94).

[0004] The biologics encompass a broad range of cell products and include specific proteins or viruses that require animal cells for propagation. For example, therapeutic proteins such as monoclonal antibodies can be synthesized in large quantities by growing genetically engineered cells in large-scale cultures (Dewar et al., Industrial implementation of in vitro production of monoclonal antibodies, *Ilar J* (2005) 46(3): 307-13). The number of such commercially valuable biologics has increased rapidly over the last decade and has led to the present widespread interest in mammalian cell culture technology (Mizrahi, A., Biologicals produced from animal cells in culture-an overview, *Biotechnol. Adv.* (1988) 6(2): 207-20).

[0005] The major advantage of using cell culture for any of the above applications is the consistency and reproducibility of results that can be obtained from using a batch of clonal cells. The need for cell culture, especially at large scale, became apparent

with the need for viral vaccines. Major epidemics of polio in the 1940s and 1950s promoted a lot of effort to develop an effective vaccine. In 1949, it was shown that poliovirus could be grown in cultures of human cells, which led to considerable interest in the development of large quantities of the polio vaccine using cell culture (Ligon, B.L., Thomas Huckle Weller MD: Nobel Laureate and research pioneer in poliomyelitis, varicella-zoster virus, cytomegalovirus, rubella, and other infectious diseases, *Semin. Pediatr. Infect. Dis.* (2002) 13(1): 55-63). The polio vaccine, produced from de-activated virus, became one of the first commercial products of cultured animal cells (Furesz, J., Developments in the production and quality control of poliovirus vaccines - Historical perspectives, *Biologicals* (2006)).

[0006] Many components of cell culture media are obtained from animal sources, including lactoferrin, transferrin and serum albumin. These components are extracted from animal sources, purified, and then combined with other inorganic ingredients to constitute cell culture media (Mizrahi, A. & Lazar, A., Media for cultivation of animal cells: an overview, *Cytotechnology* (1988) 1: 199-214). Cell culture components produced in this way have several undesirable features. For one, there is no way to ensure that extraneous animal products are completely excluded from the component, no matter how precise the purification techniques. Animal-derived components can carry the risk of contamination of pathogens of animal and human origin such as BSE, HIV and hepatitis virus (Chamberland et al., Emerging infectious disease issues in blood safety, *Emerg. Infect. Dis.* (2001) 7(3 Suppl): 552-3; Hepatitis C: A Brief Review, *America's Blood Centers* (October 1998) vol. 1, issue 3 (Strong, M. ed.), available at <http://www.americasblood.org/index.cfm?fuseaction=display.showPage&pageID=133>; Weinberg et al., Legal, financial, and public health consequences of HIV contamination of blood and blood products in the 1980s and 1990s, *Ann. Intern. Med.* (2002) 136(4): 312-9).

[0007] For another, small proteinaceous particles, such as prions, could be present and current scientific evidence suggests that even a very small number could result in disease. In a recent case, a healthy subject died from possible transmission of variant Creutzfeldt-Jakob disease from blood transfusion (Llewelyn et al., Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion, *Lancet* (2004)

363(9407): 417-21). This raises concerns regarding the consistent safety of blood and blood-derived products (Bird, S.M., Recipients of blood or blood products "at vCJD risk," *BMJ* (2004) 328(7432): 118-9). Because of such safety concerns, regulators are encouraging replacing animal components with recombinant proteins in vaccine production and other applications of cell culture techniques (Egan, W.M., Bovine-derived products used in the manufacture and formulation of vaccines: current policies and issues for the future (2004), available at <http://www.fda.gov/cber/summaries/pda092004we.pdf>; European Medicine Agency (EMA), CPMP position statement on Crutzfeldt-Jakob disease and plasma-derived and urine-derived medicinal products (2003), available at <http://www.emea.eu.int/pdfs/human/press/pos/287902en.pdf>; World Health Organization (WHO), Variant Creutzfeldt-Jakob disease (2002), available at <http://www.who.int/mediacentre/factsheets/fs180/en/>). Further, many users may be hesitant to use products from cell culture media that contain animal components for religious or moral reasons (Sarkar, S., Use of animal products in vegetarians and others, *Anaesthesia* (2005) 60(5): 519-20).

[0008] Therefore, there is a need to produce components for incorporation into cell culture media that is not derived from, or produced by, animal sources, yet still retain their functional value for cell cultures.

SUMMARY OF THE INVENTION

[0009] Accordingly, it is an objective of the invention to provide cell culture media or media supplements containing components derived from plant cells, which when used in cell culture, results in the same or improved growth and productivity of cells as compared to the use of media containing animal-derived components.

[0010] One embodiment of the invention comprises a cell culture media with at least one plant-produced heterologous protein as a cell culture media component.

[0011] Another embodiment of the invention comprises a method for producing an enhanced cell culture media, comprising producing at least one heterologous protein in a plant cell and combining the at least one plant-produced heterologous protein with a cell culture media.

[0011] Another embodiment of the invention comprises a cell culture media produced by a process comprising producing at least one heterologous protein in a plant cell and combining at least one plant-produced heterologous protein with a cell culture media.

[0012] Another embodiment of the invention discloses that in a cell culture media having one or more proteinaceous cell culture media components, the improvement comprising at least one plant-produced heterologous protein as a cell culture media component, wherein the heterologous protein is produced by the following process:

a) transforming a plant cell with a chimeric gene comprising:

(i) a promoter from the gene of a seed storage protein;

(ii) a first DNA sequence, operably linked to the promoter, encoding a seed storage protein, and

(iii) a second DNA sequence, operably linked to the promoter, encoding the heterologous protein, wherein the first and second DNA sequences are linked in translation frame and together encode a fusion protein comprising the storage protein and the heterologous protein; and

b) growing a plant from the transformed plant cell for a time sufficient to produce seeds containing the heterologous protein. The embodiment may optionally include purifying the heterologous protein from the harvested seeds.

[0013] Another embodiment of the invention comprises a method for producing a cell culture media having at least one plant-produced heterologous protein as a cell culture media component, the method comprising:

a) transforming a plant cell with a chimeric gene comprising:

(i) a promoter from the gene of a seed storage protein;

(ii) a first DNA sequence, operably linked to the promoter, encoding a seed storage protein, and

(iii) a second DNA sequence, operably linked to the promoter, encoding the heterologous protein, wherein the first and second DNA sequences are linked in translation frame and together encode a fusion protein comprising the storage protein and the heterologous protein;

- b) growing a plant from the transformed plant cell for a time sufficient to produce seeds containing the heterologous protein;
- c) harvesting the seeds from the plant; and
- d) combining the heterologous protein with a cell culture media.

[0014] Another aspect of the invention comprises a method for creating a recombinant plant cell that can produce components that may be incorporated into cell culture media or supplement for cell culture media.

[0015] Another aspect of the invention comprises a method of transforming a plant cell by incorporating a DNA segment that encodes for a component of cell culture media.

[0016] Another aspect of the invention comprises a method of transforming a rice cell by incorporating a DNA segment that encodes for components of cell culture media such as amino acids, growth factors, and other cell culture proteins including lactoferrin and human serum albumin.

[0017] Another aspect of the invention comprises a cell culture medium with components that are derived from plants, and more preferably all the organic ingredients are derived exclusively from non-animal sources.

[0018] Another aspect of the invention comprises a method for the production of cell culture media, the method comprising incorporating into cell culture media components derived from recombinant plant cells.

[0019] Another aspect of the invention comprises of the use of the media supplemented with plant-derived components to improve cell growth and productivity in cell cultures.

[0020] Another aspect of the invention comprises improved cell culture media comprising one or more media ingredients and as a supplement to one or more cell culture media components derived from plant cells.

[0021] Another aspect of the invention comprises a method for achieving high growth rate of culture cells and high productivity of culture cells by culturing the culture cell in the improved cell culture media.

[0022] Another aspect of the invention comprises a method of producing an improved cell culture media comprising a) obtaining a plant cell transformed with a

vector containing a plant-based promoter and a gene encoding a cell culture media component, b) cultivating the transformed plant cells to set seeds, c) harvesting the mature seeds, d) extracting and purifying of the cell culture components from the seed, and e) adding the components to cell culture media.

BRIEF DESCRIPTION OF THE FIGURES

[0023] Figure 1 is a comparison of the codon-optimized epidermal growth factor sequence ("Egfactor") with a native epidermal growth factor sequence ("Native Gene"), aligned to show 53 codons in the mature sequences, with 27 (51%) codon changes and 30 (19%) nucleotide changes.

[0024] Figure 2 is a restriction map of the 3,877 bp plasmid, API303 (pGt1-EGF v2.1), showing an expression cassette for epidermal growth factor (EGF), and containing a rice Gt1 promoter, a Gt1 signal peptide, codon optimized EGF, a Nos terminator and an ampicillin resistance selectable marker.

[0025] Figure 3 is a restriction map of the 4,142 bp plasmid, API270 (pGlb-EGF v2.1), showing an expression cassette for epidermal growth factor ("EGF"), and containing a Glb promoter, a Glb signal peptide, codon optimized EGF, a Nos terminator and an ampicillin resistance selectable marker.

[0026] Figure 4 is a Western blot analysis of recombinant human EGF ("rhEGF") in the R1 generation of transgenic rice seeds. Lane 1 indicates extracts from seeds of control untransformed Taipei 309 rice variety (*Oryza sativa*, Japonica). Lanes 2 to 5 show rhEGF expressed in the seed extracts obtained from independent transgenic rice events. Lane 6 shows a purified rhEGF standard expressed in yeast, loaded at 125 ng. Lane 7 shows a broad range of molecular weight markers.

[0027] Figure 5 is a comparison of the codon-optimized insulin-like growth factor I sequence ("Insgfact") with a native human insulin-like growth factor I sequence ("native gene"), aligned to show 70 codons in the mature sequences, with 40 (57%) codon changes and 47 (22%) nucleotides changes.

[0028] Figure 6 is a restriction map of the 4,194 bp plasmid, API271 (pGlb-IGF v2.1), showing an expression cassette for insulin-like growth factor I ("IGF"), and containing a Glb promoter, a Glb signal peptide, codon optimized IGF, a Nos terminator and an ampicillin resistance selectable marker.

[0029] Figure 7 is a restriction map of the 3,928 bp plasmid, API304 (pGt1-IFG v2.1), showing an expression cassette for insulin-like growth factor I ("IGF"), and containing a rice Gt1 promoter, a Gt1 signal peptide, codon optimized IGF, a Nos terminator and an ampicillin resistance selectable marker.

[0030] Figure 8 is a Western blot analysis of recombinant human IGF-I ("rhIGF") expressed in the R1 generation of transgenic rice seeds. Lane 1 shows rice seed extract from seeds of control untransformed rice variety Taipei 309. Lanes 2 to 8 show rhIGF expressed in seed extracts obtained from seven independent transgenic rice events. Lane 9 shows a purified rhIGF-1 standard expressed in yeast, loaded at 1 µg. Lane 10 shows a broad range of molecular weight markers.

[0031] Figure 9 is a comparison of the codon-optimized intestinal trefoil factor sequence ("Trefoil") with a native intestinal trefoil factor sequence ("Native Gene"), aligned to show 60 codons in the mature sequences, with 26 (43%) codon changes and 28 (15%) nucleotide changes.

[0032] Figure 10 is a restriction map of the 4,163 bp plasmid, API269 (pGlb-ITF-nos), showing an expression cassette for intestinal trefoil factor ("ITF"), and containing a Glb promoter, a Glb signal peptide, codon optimized ITF, a Nos terminator and an ampicillin resistance selectable marker.

[0033] Figure 11 is a restriction map of the 3,889 bp plasmid, API307 (pGt1-ITF-nos), showing an expression cassette for intestinal trefoil factor (ITF), and containing a rice Gt1 promoter, a Gt1 signal peptide, codon optimized ITF, a Nos terminator and an ampicillin resistance selectable marker.

[0034] Figure 12 is a Western blot analysis of recombinant human ITF ("rhITF") expression in the R1 generation of transgenic rice seeds. Lane 1 indicates extracts from seeds of control untransformed Taipei 309 rice variety. Lanes 2 and 3 show rhITF expressed in the seed extracts obtained from two independent transgenic rice events. Lane 4 indicates a purified rhITF standard expressed in yeast, loaded at 1 µg. Lane 5 shows a broad range of molecular weight markers.

[0035] Figure 13 is a comparison of the codon-optimized human lactoferrin sequence ("cod opt lac") with a native human lactoferrin sequence ("native lac"), aligned

to show 693 codons, with 413 (59.6%) codon changes and 467 (22.5%) nucleotide changes.

[0036] Figure 14 is a plasmid map of the 5,817 bp plasmid, API164 (GT1-Lac), showing an expression cassette for human lactoferrin and containing a Gt1 promoter, a Gt1 signal peptide, codon optimized human lactoferrin, a Nos terminator and a kanamycin resistance selectable marker.

[0037] Figure 15 shows the results of a SDS-PAGE analysis for the expression of recombinant human lactoferrin. Total proteins from rice seed extracts were suspended in Laemli sample buffer, run on a gradient gel and stained with Coomassie blue. Lane 1 is the molecular weight marker. Lanes 3 to 6 are purified human derived lactoferrin (Sigma Chemical, USA). Lanes 8 to 13 are single seed extracts from homozygous independent transgenic rice lines and lane 14 is a seed extract from non-transformed rice variety Taipei 309.

[0038] Figure 16 is a stable expression of recombinant human lactoferrin in transgenic rice grains from R₂ through R₁₀ generations. Total soluble proteins from 1 g of brown rice flour was extracted with 40 ml of extraction buffer and clarified by centrifugation. The extract was analyzed via ELISA. Extraction was repeated three times and standard deviation is shown as an error bar.

[0039] Figure 17 shows DNA and protein sequence of fusion between Gt1 signal peptide (Gt1 SP) and codon-optimized human serum albumin (OPTIMIZED HSA) sequence based on native protein sequence derived from P02768 (Swiss-Prot).

[0040] Figure 18 is a plasmid map of the 5,496 bp plasmid, API504 (GT1-HSA), showing an expression cassette for human serum albumin and containing a Gt1 promoter, a Gt1 signal peptide, codon optimized human serum albumin, a Nos terminator and a kanamycin resistance selectable marker.

[0041] Figure 19 is a plasmid map of the 12,388 bp plasmid, API508 (JH/GT1-HSA), showing an expression cassette for human serum albumin and containing a Gt1 promoter, a Gt1 signal peptide, codon optimized human serum albumin, a Nos terminator and a kanamycin resistance selectable marker.

[0042] Figure 20 shows the effect of three forms of recombinant human lactoferrin on cell growth. The three forms of lactoferrin are asis-lactoferrin, apo-

lactoferrin and holo-lactoferrin. Asis-lactoferrin is the same as partial-lactoferrin with approximately 50% iron saturation. The baseline is with basal media and the rest is baseline supplemented with various concentration of recombinant human lactoferrin as indicated in the graph. Cell growth is measured as thymidine incorporation.

[0043] Figure 21 shows the effect of three forms of recombinant human lactoferrin on cell growth. The three forms of lactoferrin are asis-lactoferrin, apo-lactoferrin and holo-lactoferrin. Asis-lactoferrin is the same as partial-lactoferrin with approximate 50% iron saturation. The baseline is with basal media plus 5% fetal calf serum and the rest are baseline supplemented with epidermal growth factor, 5% FCS or recombinant human lactoferrin at a final concentration of 1 mg/ml. Cell growth is measured as number of cells/ml.

[0044] Figure 22 shows cell culture media supplemented with recombinant human lactoferrin (LACROMIN™) expressed in rice grain promotes hybridoma cell growth and increases hybridoma cell number as compared to animal derived transferrin. FBS is fetal bovine serum. AFM6 is serum-free cell culture media derived from KC Bio, Kansas. AFM6-Fe is a serum-free media without iron.

[0045] Figure 23 shows the effect of recombinant human serum albumin (rHSA) and plasma-derived human serum albumin (pHSA) on the growth of hybridoma AE1 cells in control medium (CM) containing reduced serum (1% FBS).

[0046] Figure 24 shows the effect of recombinant human serum albumin (rHSA) and plasma-derived human serum albumin (pHSA) on the growth of hybridoma AE1 cells in serum-free medium (SMF).

DETAILED DESCRIPTION

[0047] Unless otherwise indicated, all terms used herein have the meanings given below or are generally consistent with same meaning that the terms have to those skilled in the art of the present invention. Practitioners are particularly directed to Sambrook et al. (1989) *Molecular Cloning: A Laboratory Manual* (Second Edition), Cold Spring Harbor Press, Plainview, N.Y., Ausubel FM et al. (1993) *Current Protocols in Molecular Biology*, John Wiley & Sons, New York, N.Y., and Gelvin and Schilperoot, eds. (1997) *Plant Molecular Biology Manual*, Kluwer Academic Publishers, The Netherlands for definitions and terms of the art.

[0048] General and specific techniques for producing proteins from plant cells may be obtained from the following patents and applications, each of which is incorporated herein in its entirety by reference: U.S. Pat. Appl. Pub. No. 2003/0172403 A1 ("Plant Transcription Factors and Enhanced Gene Expression"); U.S. Pat. No. 6,991,824 ("Expression of Human Milk Proteins in Transgenic Plants"); U.S. Pat. Appl. Pub. No. 2003/0221223 ("Human Blood Proteins Expressed in Monocot Seeds"); U.S. Pat. Appl. Pub. No. 2004-0078851 ("Production of Human Growth Factors in Monocot Seeds"); U.S. Pat. Appl. Pub. No. 2004/0063617 ("Method of Making an Anti-infective Composition for Treating Oral Infections"); and international application no. PCT/US2004/041083 ("High-level Expression of Fusion Polypeptides in Plant Seeds Utilizing Seed-Storage Proteins as Fusion Carriers"). Other general and specific techniques for producing proteins from plant cells may be obtained, for example, from the following references, each of which is incorporated herein in its entirety by reference: U.S. Patent No. 5,693,507, U.S. Patent No. 5,932,479, U.S. Patent No. 6,642,053, and 6,680,426 (each titled "Genetic Engineering of Plant Chloroplasts"); U.S. Pat. Appl. Pub. No. 2005/0066384 ("Site-Targeted Transformation Using Amplification Vectors"); U.S. Pat. Appl. Pub. No. 2005/0221323 ("Amplification Vectors Based on Trans-Splicing"); U.S. Pat. Appl. Pub. No. 2006/0026718 ("Method of Controlling Cellular Processes in Plants"); and U.S. Pat. Appl. Pub. No. 2006/0075524 ("Method of Controlling A Cellular Process in a Multi-Cellular Organism"); Marillonnet et al., *Systemic Agrobacterium tumefaciens*-mediated transfection of viral replicons for efficient transient expression in plants, *Nature Biotech.* (2005) 23(6): 718-723.

[0049] The polynucleotides of the invention may be in the form of RNA or in the form of DNA, and include messenger RNA, synthetic RNA and DNA, cDNA, and genomic DNA. The DNA may be double-stranded or single-stranded, and if single-stranded may be the coding strand or the non-coding (anti-sense, complementary) strand.

[0050] The term "stably transformed" with reference to a plant cell means the plant cell has a non-native (heterologous) nucleic acid sequence integrated into its genome which is maintained through two or more generations.

[0051] By "host cell" is meant a cell containing a vector and supporting the replication and/or transcription and/or expression of the heterologous nucleic acid sequence. Preferably, according to the invention, the host cell is a plant cell. Other host cells may be used as secondary hosts, including bacterial, yeast, insect, amphibian or mammalian cells, to move DNA to a desired plant host cell.

[0052] A "plant cell" refers to any cell derived from a plant, including undifferentiated tissue (e.g., callus) as well as plant seeds, pollen, propagules, embryos, suspension cultures, meristematic regions, leaves, roots, shoots, gametophytes, sporophytes and microspores.

[0053] The term "mature plant" refers to a fully differentiated plant.

[0054] The term "seed product" includes, but is not limited to, seed fractions such as de-hulled whole seed, flour (seed that has been de-hulled by milling and ground into a powder) a seed extract, preferably a protein extract (where the protein fraction of the flour has been separated from the carbohydrate fraction), malt (including malt extract or malt syrup) and/or a purified protein fraction derived from the transgenic grain.

[0055] The term "biological activity" refers to any biological activity typically attributed to that protein by those skilled in the art.

[0056] "Monocot seed components" refers to carbohydrate, protein, and lipid components extractable from monocot seeds, typically mature monocot seeds.

[0057] "Seed maturation" refers to the period starting with fertilization in which metabolizable reserves, e.g., sugars, oligosaccharides, starch, phenolics, amino acids, and proteins, are deposited, with and without vacuole targeting, to various tissues in the

seed (grain), e.g., endosperm, testa, aleurone layer, and scutellar epithelium, leading to grain enlargement, grain filling, and ending with grain desiccation.

[0058] "Maturation-specific protein promoter" refers to a promoter exhibiting substantially up-regulated activity (greater than 25%) during seed maturation.

[0059] The term "growth factor" refers to proteins, or biologically active fragments thereof, including, without limitation, epidermal growth factor (EGF), keratinocyte growth factors (KGF) including KGF-1 and KGF-2, insulin-like growth factors (IGF) including IGF-I and IGF-II, intestinal trefoil factor (ITF), transforming growth factors (TGF) including TGF- α and - β 1-3, granulocyte colony-stimulating factor (GCSF), nerve growth factor (NGF) including NGF- β , and fibroblast growth factor (FGF) including FGF-1-19 and -12 β , and biologically active fragments of these proteins. The sequences of these and other growth factors are well-known to those of ordinary skill in the art.

[0060] "Heterologous DNA" refers to DNA which has been introduced into plant cells from another source, or which is from a plant source, including the same plant source, but which is under the control of a promoter that does not normally regulate expression of the heterologous DNA.

[0061] "Heterologous protein" is a protein encoded by a heterologous DNA. The proteins include, but are not limit to, growth factor(s), lactoferrin, transferrin, albumin, insulin, and fractions thereof, growth hormone and fractions thereof, Fibronectin (human) – attachment factor, Lamin (Mouse) – attachment factor, collagenase, platelet derived growth factor, Human brain-derived neurotrophic factor (BDNF), glial-derived neurotrophic factor (GDNF), thymic factors, haptocorin, lactahedrin, lactoperoxidase. Alpha-fetoprotein, immunoglobulin, alpha-lactalbumin.

[0062] As used herein, the terms "native" or "wild-type" relative to a given cell, protein, polypeptide, nucleic acid, trait or phenotype, refers to the form in which that is typically found in nature.

[0063] As used herein, the term "purifying" is used interchangeably with the term "isolating" and generally refers to any separation of a particular component from other components of the environment in which it is found or produced. For example, purifying a recombinant protein from plant cells in which it was produced typically means subjecting transgenic protein-containing plant material to separation techniques such as

sedimentation, centrifugation, filtration, and chromatography. The results of any such purifying or isolating step(s) may still contain other components as long as the results enrich for the component of interest.

[0064] As used herein, the terms “transformed” or “transgenic” with reference to a host cell means the host cell contains a non-native or heterologous or introduced nucleic acid sequence that is absent from the native host cell. Further, “stably transformed” in the context of the present invention means that the introduced nucleic acid sequence is maintained through two or more generations of the host, which is preferably (but not necessarily) due to integration of the introduced sequence into the host genome.

[0065] “Cell culture media” refers to media for cell culture purpose which includes complete media, basal media or basal media supplemented with cell culture media component, cell culture media supplement, or media with various amounts of serum or chemically defined media.

[0066] “Cell culture media component” refers any heterologous proteins for use as a supplement to cell culture media.

[0067] “Cell culture media ingredient” includes cell culture media components, proteins, peptides, hormones, carbohydrates, amino acids, lipids, vitamins, antibiotics, organic and inorganic salts.

[0068] “Cell culture media supplement” refers to a combination of one or multiple cell culture media components with or without other ingredients for addition to cell culture media.

[0069] Most cells in culture grow best at 37°C and at pH 7.4 with appropriate media. Typically, cell culture media contains carbohydrates, amino acids, various salts, bicarbonate to maintain pH, vitamins and hormones, and phenol red as pH indicator. Examples of cell culture media that can be formed include: Dulbecco’s Modified Eagle’s Medium (DME), Ham’s Nutrient Mixtures, MCDB Media, Minimum Essential Medium Eagle, RPMI Media, Ames’ Media, BGJb Medium (Fitton-Jackson Modification), Click’s Medium, CMRL-1066 Medium, Fischer’s Medium, Glasgow Minimum Essential Medium (GMEM), Iscove’s Modified Dulbecco’s Medium (IMDM), L-15 Medium (Leibovitz),

McCoy's 5A Modified Medium, NCTC Medium, Swim's S-77 Medium, Waymouth Medium, and William's Medium E.

[0070] Frequently, cell culture media is supplemented with serum at concentration of 5 to 10%. Serum is a complex mixture containing undefined essential matter for cell growth. Commonly used serum is fetal calf serum (FCS) and fetal bovine serum (FBS). Due to its nature of complex mixture, lack of consistency and potential risk of pathogen contamination, cell culture industries and regulatory agencies are seeking alternatives to adding serum to cell culture media.

[0071] Since cells grow poorly in basal media, the basal media is then supplemented with various growth factors, hormones, and other essential components to generate serum-free media but maintaining the same cell growth rate as in serum-based media. Human transferrin or bovine transferrin is added as a source of iron. Typically, serum-free media contains insulin, serum albumin, transferrin, insulin-like growth factor and epidermal growth factor. Other proteins such as lactoferrin have also been shown to be able to promote cell growth. Each component provides a distinct function in cell growth. In the art, these protein components are animal-derived. With the increase in the concern of potential pathogen contamination from animal sourced material, cell culture industries are trying to develop animal-component-free media. While some successes have been made with the use of plant-based hydrolysates or recombinant protein produced with microbial system, plant-based hydrolysate is an undefined mixture of components and recombinant protein from microbial sources are too expensive to use in routine cell culture. An alternative source of non-animal-derived components is urgently needed for cell culture industries.

[0072] The cell culture media components produced by the methods to be described in the following sections are entirely plant-based and may be combined with inorganic salts such as NaCl, KCl, NaH_2PO_4 , NaHCO_3 , CaCl_2 , and MgCl_2 and other ingredients such as amino acids, vitamins, growth factors, sugars, and antibiotics to form a variety of different cell culture media.

[0073] Expression vectors for use in the present invention are chimeric nucleic acid constructs (or expression vectors or cassettes), designed for operation in plants, with associated upstream and downstream sequences.

[0074] In general, expression vectors for use in practicing the invention include the following operably linked elements that constitute a chimeric gene: a promoter derived from a gene encoding a plant protein, operatively linked to a gene encoding a heterologous protein. The vector can include a promoter from the gene of a maturation-specific monocot plant storage protein, a first DNA sequence, operably linked to the promoter, encoding a monocot plant seed-specific signal sequence (such as an N-terminal leader sequence or a C-terminal trailer sequence) capable of targeting a polypeptide linked thereto to an endosperm cell, preferably an endosperm-cell organelle, such as a protein storage body, and a second DNA sequence, linked in translation frame with the first DNA sequence, encoding a cell culture media component. The signal sequence is preferably cleaved from the cell culture media component in the plant cell.

[0075] The chimeric gene, in turn, is typically placed in a suitable plant-transformation vector having (i) companion sequences upstream and/or downstream of the chimeric gene which are of plasmid or viral origin and provide necessary characteristics to the vector to permit the vector to move DNA from bacteria to the desired plant host; (ii) a selectable marker sequence; and (iii) a transcriptional termination region generally at the opposite end of the vector from the transcription initiation regulatory region.

[0076] Numerous types of appropriate expression vectors, and suitable regulatory sequences are known in the art for a variety of plant host cells. The promoter region is chosen to be regulated in a manner allowing for induction under seed-maturation conditions. In one aspect of this embodiment of the invention, the expression construct includes a promoter which exhibits specifically up-regulated activity during seed maturation. Promoters for use in the invention are typically derived from cereals such as rice, barley, wheat, oat, rye, corn, millet, triticale or sorghum. Examples of such promoters include the maturation-specific promoter region associated with one of the following maturation-specific monocot plant storage proteins: rice glutelins, oryzins, and prolamines, barley hordeins, wheat gliadins and glutelins, maize zeins and glutelins, oat glutelins, and sorghum kafirins, millet pennisetins, and rye secalins.

[0077] One embodiment of the present invention involves high-level expression of heterologous molecules that are components of cell culture media. These components can be expressed in a plant cell by a chimeric gene comprising the gene(s) encoding the desired component operably linked with an endogenous plant protein encoding gene. In a preferred embodiment the endogenous plant encoding gene is a rice seed storage protein gene for expression in a rice mature seed expression system.

[0078] The expressed polypeptide may be a multi-domain polypeptide with one domain being the heterologous or exogenous cell culture component and the other being the endogenous plant protein. At least one selective purification tag and/or at least one specific protease cleavage site may be provided for eventual release of the cell culture media component from the monocot seed storage protein carrier. For example, a strategic methionine or tryptophan residue providing a chemical cleavage site may be engineered in frame between the domains for release of the cell culture component from the endogenous plant protein. This technique is useful for cell culture media components that have protein portions or are proteins, for example lactoferrin, human serum albumin, and human growth factors.

[0079] Other selective protease cleavage sites include, but are not limited to enterokinase (ek), Factor Xa, thrombin, V8 protease, GENENASE™ (a variant of subtilisin BPN'), α -lytic protease or tobacco etch virus protease. Alternatively, cleavage of the fusion protein could be performed via chemical cleaving agents such as cyanogen bromide or N-chlorosuccinimide.

[0080] The invention provides cell culture media components recombinantly produced in host monocot plant seed wherein the cell culture media component expressed comprises about 3% or greater of the total soluble protein in the monocot seed. Thus, for example, the yield of total soluble protein which comprises the cell culture media component targeted for production can be from about 3% to about 5%, from about 5% to about 10%, from about 10% to about 15%, from about 15% to about 20%, from about 20% to about 25%, and from about 25% to about 30% of the total soluble protein found in the recombinantly engineered production plant seed. Additionally, for example, the yield of total soluble protein which comprises the cell culture media component targeted for production can be about 3% or greater, about 5%

or greater, about 10% or greater, about 15% or greater, about 20% or greater, and about 25% or greater.

[0081] An embodiment of the present invention is a cell culture media, comprising at least one plant-produced heterologous protein as a cell culture media component. In some embodiments, the plant is a monocot plant, such as rice, barley, wheat, rye, corn, millet, triticale, or sorghum, preferably rice. The heterologous protein is a plant protein or a non-plant protein, preferably human, which may be selected in some embodiments from the group consisting of growth factors, lactoferrin, transferrin, serum albumin, insulin, growth hormone, and fractions thereof, fibronectin attachment factor, lamin attachment factor, collagenase, platelet derived growth factor, brain-derived neurotrophic factor, glial-derived neurotrophic factor, thymic factors, haptocorin, lactahedrin, lactoperoxidase, alpha-fetoprotein, immunoglobulin, or alpha-lactalbumin. In some embodiments of the present invention, the growth factors are preferably epidermal growth factors, keratinocyte growth factors, insulin-like growth factors, intestinal trefoil factors, transforming growth factors, granulocyte colony-stimulating factors, nerve growth factors, fibroblast growth factors, or biologically active fragments thereof.

[0082] In some embodiments, the cell culture media is a reduced serum or serum-free medium. In other embodiments, the cell culture media is disclosed as a complete media, basal media, or basal media supplemented with a cell culture media component.

[0083] Another embodiment of the present invention is a method for producing a cell culture media, comprising producing at least one heterologous protein in a plant cell and combining the at least one plant-produced heterologous protein with a cell culture media.

[0084] Another embodiment of the present invention is a cell culture media produced by a process comprising producing at least one heterologous protein in a plant cell and combining at least one plant-produced heterologous protein with a cell culture media.

[0085] Another embodiment of the present invention is an improved cell culture media having one or more proteinaceous cell culture media components, the improvement comprising at least one plant-produced heterologous protein as a cell

culture media component, wherein the heterologous protein is produced by the following process:

a) transforming a plant cell with a chimeric gene comprising:

(i) a promoter from the gene of a seed storage protein;

(ii) a first DNA sequence, operably linked to the promoter, encoding a seed storage protein, and

(iii) a second DNA sequence, operably linked to the promoter, encoding the heterologous protein, wherein the first and second DNA sequences are linked in translation frame and together encode a fusion protein comprising the storage protein and the heterologous protein; and

b) growing a plant from the transformed plant cell for a time sufficient to produce seeds containing the heterologous protein. In some embodiments, the heterologous protein is purified from the harvested seeds. In some embodiments, the heterologous protein constitutes at least about 3.0% of the total soluble protein in the harvested seeds.

[0086] Another embodiment of the present invention is a method for producing a cell culture media having at least one plant-produced heterologous protein as a cell culture media component, the method comprising:

a) transforming a plant cell with a chimeric gene comprising:

(i) a promoter from the gene of a seed storage protein;

(ii) a first DNA sequence, operably linked to the promoter, encoding a seed storage protein, and

(iii) a second DNA sequence, operably linked to the promoter, encoding the heterologous protein, wherein the first and second DNA sequences are linked in translation frame and together encode a fusion protein comprising the storage protein and the heterologous protein;

b) growing a plant from the transformed plant cell for a time sufficient to produce seeds containing the heterologous protein;

c) harvesting the seeds from the plant; and

d) combining the heterologous protein with a cell culture media.

[0087] Another embodiment of the present invention is a method of producing monocot seeds, preferably rice grains, that can express the desired cell culture media component, comprising:

- a) transforming a monocot plant cell with a chimeric gene comprising:
 - (i) a promoter from the gene of a monocot seed storage protein;
 - (ii) a first DNA sequence, operably linked to the promoter, encoding a monocot seed storage protein; and
 - (iii) a second DNA sequence, operably linked to the promoter, encoding a cell culture media component,wherein the first and second DNA sequences are linked in translation frame and together encode a fusion protein comprising the storage protein and the cell culture media component;
- b) growing a monocot plant from the transformed monocot plant cell for a time sufficient to produce seeds containing the cell culture media component; and
- c) harvesting the seeds from the monocot plant.

[0088] Another aspect of the present invention is a method of utilizing monocot seed storage proteins as fusion protein carriers, comprising the above method.

[0089] The invention also includes a chimeric gene, comprising:

- (i) a promoter from the gene of a monocot seed storage protein;
- (ii) a first DNA sequence, operably linked to the promoter, encoding a monocot seed storage protein; and
- (iii) a second DNA sequence, operably linked to the promoter, encoding a cell culture media component;

wherein the first and second DNA sequences are linked in translation frame and together encode a fusion protein comprising the storage protein and the cell culture media component.

[0090] The monocot seed storage protein may be at the N-terminal or C-terminal side of the cell culture media component in the fusion protein. It is preferred that the monocot seed storage protein be located at the N-terminal side of the cell culture media component.

[0091] Preferably, the monocot plant comprises rice, barley, wheat, rye, corn, millet, triticale, or sorghum. More preferably, the monocot plant is rice.

[0092] All publications, patents and patent applications are herein expressly incorporated by reference in their entirety to the same extent as if each individual publication, patent or patent application was specifically and indicated individually to be incorporated by reference in its entirety.

[0093] The following examples illustrate but are not intended in any way to limit the scope of the invention.

EXAMPLES

Example 1: Expression of recombinant human growth factors

[0094] In general, expression vectors were constructed using standard molecular biological techniques. The vectors contain a heterologous protein coding sequence for certain growth factors under the control of a rice tissue-specific promoter, as further described below.

[0095] The nucleotide sequence of the promoter and the nucleotide sequence of the signal peptide of the rice glutelin-1 (Gt1) gene were cloned based on the published Gt1 gene sequence. The nucleotide sequence of the promoter and the nucleotide sequence of the signal peptide of the rice globulin (Glb) gene were cloned based on the published Glb gene sequence.

A. Generation of human EGF expression vector

[0096] The human EGF gene was codon optimized as shown in Figure 1, and synthesized by Operon Technologies (CA, USA) (SEQ ID NO: 1). For expression of EGF in rice seeds, the codon optimized gene was operably linked to the rice endosperm specific glutelin (Gt1) promoter, Gt1 signal peptide and NOS terminator in pAPI303 (Figure 2), and to the rice endosperm specific globulin (Glb) promoter, Glb signal peptide and NOS terminator in pAPI270 (Figure 3). The transgenic plant expressing EGF was generated, and plant-generated recombinant EGF was detected, as shown in Figure 4 and as exemplified herein.

B. Generation of human IGF-I expression vector

[0097] The IGF-I gene was codon optimized as shown in Figure 5, and synthesized by Operon Technologies (CA, USA) (SEQ ID NO: 3). For expression of

IGF-I in rice seeds, the codon optimized gene was operably linked to the rice endosperm specific glutelin (Gt1) promoter, Gt1 signal peptide and NOS terminator in pAPI304 (Figure 7), and to the rice endosperm specific globulin (Glb) promoter, Glb signal peptide and NOS terminator in pAPI271 (Figure 6). The transgenic plant expressing IGF-I was regenerated, and plant-generated recombinant IGF-I was detected as shown in Figure 8 and as exemplified herein.

C. Generation of human ITF

[0098] The ITF gene was codon optimized as shown in Figure 9, and synthesized by Operon Technologies (CA, USA) (SEQ ID NO: 5). For expression of ITF in rice seeds, the codon optimized gene was operably linked to the rice endosperm specific glutelin (Gt1) promoter, Gt1 signal peptide and NOS terminator in pAPI307 (Figure 11), and to the rice endosperm specific globulin (Glb) promoter, Glb signal peptide and NOS terminator in pAPI269 (Figure 10). The transgenic plant expressing ITF was generated, and plant-generated recombinant ITF was detected as shown in Figure 12 and as exemplified herein.

D. Western blot analysis for all growth factors

[0099] Both untransformed (rice variety Taipei 309) and transgenic rice seeds (~10 pooled R1 seed from individual transgenic plants expressing either EGF, IGF-I or ITF) were ground in 1 ml of 0.35 M NaCl in phosphate buffered saline (PBS), pH 7.4, using an ice-cold mortar and pestle. The resulting extract was centrifuged at 14,000 rpm at 4°C for 10 min. Cleared supernatant was collected and ~20 ug of this soluble protein extract was re-suspended in sample loading buffer, and loaded onto a pre-cast 10-20% polyacrylamide tricine gel (Novex) and subjected to SDS-PAGE. After electrophoresis, the gel was blotted to a 0.45 µm nitrocellulose membrane. The membrane was blocked with 5% non-fat dry milk in PBS pH 7.4 for 2 hrs followed by three washes with PBS for 10 min each. A primary rabbit polyclonal antibody prepared against EGF(Sigma), IGF-I (Sigma) or ITF (GI Company) was used at 1:2000 dilution in PBS. Bands were developed using goat anti-rabbit antibody coupled to the BCIP/NBT substrate system (Sigma). Results are shown in Figures 4, 8 and 12, respectively.

Example 2: Expression of recombinant human lactoferrin

A. An Expression Vector For Human Lactoferrin Expression In Transgenic Rice

[0100] Complete nucleotide sequence of human mammary gland lactoferrin was codon optimized and synthesized by Operon Technologies (CA, USA). Human milk lactoferrin gene (Genbank accession number: HSU07642) was re-synthesized with codons most frequently used in translation of rice seed proteins in order to obtain optimal level of expression (Figure 13). Although numbers of codons changed accounted for 22.46% of the entire sequence, amino acid composition remains identical to native human lactoferrin. The plasmid containing the codon-optimized gene was called Lac-ger. Lac-ger was digested with SmaI/XhoI and the fragment containing the lactoferrin gene was cloned into pAPI141 that was partially digested with NaeI and completely digested with XhoI. For expression of hLF in rice seeds, the codon-optimized gene was operably linked to the rice endosperm-specific glutelin (Gt1) promoter and NOS terminator. The resulting plasmid was designated pAPI164 (Figure 14).

B. Production system

[0101] Rice variety Taipei 309 (*Oryza sativa*, Japonica) was selected as the production system for recombinant human lactoferrin (rhLF) and transgenic rice events were generated by the particle bombardment of embryogenic rice calli with the plasmid pAPI164 and a companion marker plasmid containing the hygromycin phosphotransferase gene as a selectable marker. Fully developed, fertile rice plants were obtained by this procedure.

C. High Level Protein Expression of recombinant human lactoferrin in rice grain

[0102] Expression of recombinant human lactoferrin was under the control of the seed maturation-specific promoter Gt1. The high level expression of recombinant human lactoferrin is evident in Figure 15 as independent transgenic rice events were screened. Total soluble proteins from mature rice seed extracts were run on Laemli gels and stained with Coomassie blue to visualize the proteins. An ~80kD recombinant lactoferrin protein was obtained in all transgenic lines as indicated by the stained gel. Expression levels of recombinant human lactoferrin corresponded to 0.5% of seed weight. The stable expression of recombinant human lactoferrin was monitored for 10

generations. The expression level is maintained at approximately 0.5% of seed weight of brown rice (Figure 16).

Example 3: Expression of recombinant human serum albumin in rice grain

[0103] Protein sequences of human serum albumin (HSA) from various data bases were compared. The consensus sequence represented by accession number P02768 (Swiss-Prot) was used as a base for gene codon-optimization for suitable expression of human serum albumin in rice grain (Figure 17). Gene synthesis was carried out by Blue Heron (Seattle, WA) and the synthetic fragment was inserted into pUC based vector to create pUC-HSA. After confirmation of correct DNA and protein sequences, pUC-HSA was digested with MlyI and XhoI. The fragment containing codon-optimized HSA gene was inserted into pAPI405, which had been precut with NaeI and XhoI. Plasmid API405 was a derivative of pAPI141 which included Gt1 promoter, Gt1 signal sequence and a nos terminator.

[0104] Insertion of MlyI/XhoI fragment into pAPI405 resulted in pAPI504 (Figure 18). Plasmid API504 was then cleaved with HindIII and EcoRI. The HindIII/EcoRI fragment containing the entire expression cassette, Gt1 promoter, Gt1 signal sequence, codon-optimized HSA gene and nos terminator, was cloned into pJH2600 predigested with the same enzyme resulting in pAPI508 (Figure 19). Plasmid JH2600 was a shuttle vector between E coli and Agrobacterium. After DNA sequence verification, pAPI508 was moved into Agrobacterium AGL-1 for rice transformation. Plasmid API504 was also used via bombardment-based transformation following the procedure described previously. Upon transformation, transgenic plants were generated and were sent to greenhouse where transgenic R0 plants grew to maturity and set R1 seeds.

[0105] To monitor the expression of HSA in rice seeds, 10 R1 seeds from each R0 plant were extracted using 10 mL of extraction buffer (50 mM Tris-HCl pH 8.0. 150 mM NaCl). The supernatant was collected and the expression level from rice extracts was monitored by an ELISA (Bethyl Laboratories, Montgomery, TX). The results showed that the HSA expression level in rice transgenic seeds ranges from 0.01 to 0.85% of brown flour weight (0.1 to 8.5 grams/kg flour). The results of the eight events with highest expression levels are shown in the following table (Table 1).

Table 1. Recombinant HSA expression level in top eight events

Line Number	Express Level (g/kg flour)
508-3	5.5
508-17	8.0
508-71	8.7
508-73	4.0
508-77	8.5
508-83	8.5
508-101	3.0
508-113	4.0

Example 4: Purification of recombinant human lactoferrin as cell culture media component

[0106] To prepare cell culture media supplemented with recombinant human lactoferrin, recombinant human lactoferrin was purified from rice flour. Transgenic rice line (164-12) expressing high levels of rhLF was selected. This line, now named as LF164, was planted two generations per year, alternating field planting in summer and greenhouse planting in winter. For protein purification, paddy rice expressing rhLF was de-hulled (Rice Mill, PS-160, Rimac, FL), and then ground to flour (average particle size of 100 mesh) using a hammer mill (8WA, Schutte-Buffalo, NY).

[0107] Protein extraction from transgenic flour was performed by mixing two kg of rice flour and 20 L of extraction buffer (0.02 M sodium phosphate pH 6.5 and 0.3 M sodium chloride) in a 50 L tank for 1 h. At the end of the mixing period, the suspension was allowed to settle overnight or centrifuged at 3750 rpm. In both cases, the supernatant was filtered through a plate and frame filter press (Ertel Alsop, 8S, NY) using M-05 and M-70 cellulose/perlite-based filters (Ertel Alsop, NY), respectively.

[0108] The filtrate containing rhLF and other rice flour soluble proteins was loaded onto an ion exchange column for further purification. An INDEX 200/500 process column (Amersham Pharmacia Biotech, NJ) packed with SP-Sepharose fast

flow (Amersham Pharmacia Biotech, NJ) was used. The column was run at a linear flow rate of 150-200 cm/h. Packing, cleaning and testing of the resin bed was executed per manufacturer's instruction (HETP Test). The filtrate was loaded on to the resin at a linear velocity of 175 cm/h and washed with 0.02 M sodium phosphate buffer (pH 6.5) containing 0.3 M NaCl until the A_{280} returned to baseline. Recombinant hLF was eluted using 20 mM sodium phosphate buffer (pH 6.5) containing 0.8 M NaCl. The washing and elution were performed at 200 cm/h and 150 cm/h, respectively.

[0109] A Centramate module (Pall Biopharmaceutical, MA) with 1 ft² 50 kDa polyethersulfone (Pall Biopharmaceutical, MA) membrane was used for concentration and desalting (ultrafiltration) of eluted hLF. The filtration was performed at a cross flow rate of approximately 1.5 L/min and an average transmembrane pressure of 10 psig. The eluted rhLF was concentrated and desalted to a final volume of 0.25 L and then lyophilized dry. Usually, about 3 grams of purified recombinant human lactoferrin was recovered from one kilogram of transgenic rice flour.

[0110] The recombinant human lactoferrin purified from rice flour is approximately 50% saturated with iron (partial-lactoferrin). The 50% saturated recombinant human lactoferrin was then made >90% iron saturated by iron up taking treatment, resulting in holo-lactoferrin and was made <10% iron saturated by acid treatment to remove bound iron resulting in apo-lactoferrin. The purified lactoferrins (holo-, partial- and apo-) were used as cell culture media components.

Example 5: Cell culture media supplemented with recombinant human lactoferrin promotes cell growth

[0111] Recombinant human lactoferrin was added to minimal essential media (MEM) at various concentrations. This allows the test of growth factor effect of lactoferrin. The human colonic cancer cell line, HT-29, were maintained in MEM basic media containing 10% fetal calf serum (FCS). Lactoferrin samples were subsequently tested under serum-free conditions (MEM without supplementation of fetal calf serum). To assess the percentage of cells entering DNA synthesis, [³H]-thymidine (2 μ Ci/well) was included twenty four hours after the addition of lactoferrin samples and cells were left for a further 24 h. For each condition, the stimulatory or inhibitory effect of the lactoferrin solutions was measured in duplicate in six separate wells. Cell viability,

determined by the ability to exclude 0.2% trypan blue, was greater than 90%.

Proliferation assays reveal a typical 'bell shaped' dose response curve (Figure 20).

Results demonstrated these responses to lactoferrin addition and show that maximal activity of lactoferrin was at a final concentration of 1 mg/ml, for all three forms of lactoferrin. Furthermore, of the three forms, the holo-lactoferrin showed the greatest proliferative activity (Figure 20).

[0112] To determine cell viability, HT-29 Cells were seeded in 24-well plates at 5×10^5 cells per well in MEM supplemented with 5% fetal calf serum (FCS); this resulted in an attached cell number of >95% per well 24h later (as assessed by trypsinization and direct counting using a Neubauer haemocytometer). At this time, the medium was changed in identically seeded wells to one containing MEM with 5 % FCS alone or MEM with 5% FCS plus EGF, or additional 5% FCS or various forms of Lactoferrin (i.e., apo-, partial- or holo-) at a concentration of 1 mg/ml for a further 48h. At the end of this period, cell numbers were assessed. To ensure that any cells present in the supernatant at this time were included in the total cell count, supernatants were collected, centrifuged at 13,000 rpm (12,000 g) for 5 min and added to the cells following trypsinization. Result shows that recombinant human lactoferrin derived from rice promote cell growth. There were twice as many cells in wells supplemented with holo-lactoferrin as that in wells without lactoferrin (Figure 21). Both thymidine incorporation and cell count experiments indicate that recombinant human lactoferrin from rice can be added as a component to cell culture media for fast cell growth (Figures 20 and 21).

Example 6: Cell culture media supplemented with recombinant human lactoferrin promotes hybridoma cell growth

[0113] Recombinant human holo-lactoferrin was added to serum free media at various concentrations ranging from 5 to 250 mg/ml for hybridoma cell culture. Since the recombinant human lactoferrin is iron-saturated, holo-lactoferrin can provide iron for cell growth. The hybridoma cell line AE1 (ATCC) was maintained in DMEM basic media containing 5% fetal bovine serum (FBS). Lactoferrin was tested under serum-free conditions (AFM6, KC Bio, Kansas) without supplementation of fetal bovine serum. The cells were subcultured from 5% FBS to serum free media over multiple passages. At

each subculture, the cells were analyzed for total cell count and viability. In order to demonstrate that recombinant human lactoferrin can replace transferrin derived from animal source, transferrin of equal concentration was added to AFM6 media as the control. The results demonstrated that the recombinant human holo-lactoferrin can be used to replace animal-derived transferrin in cell culture media for hybridoma cell growth.

[0114] To determine the ability of holo-lactoferrin to promote cell growth, AE1 cells were sub-cultured from media containing 5% FBS to serum free media in T25 stationary flasks. The serum free media was supplemented with either animal derived transferrin; which is commonly used in the industry, or recombinant human holo-lactoferrin (LACROMIN™). This allows for a direct comparison between recombinant human holo-lactoferrin and animal derived transferrin. Each protein test was performed in triplicate with seeding densities of 5×10^5 cells per ml. To the subculture, the cells were collected by centrifugation and then seeded into fresh media with identical concentrations of either transferrin or recombinant human holo-lactoferrin (LACROMIN™). Each flask was analyzed on day 1 and day 3, following the subculture, for cell number and viability. An average cell count is given in Figure 22 for two passages. As can be seen, the cell viability and cell number when using recombinant human holo-lactoferrin are much higher than that without lactoferrin and equivalent to that of animal derived transferrin, indicating that plant-derived recombinant human holo-lactoferrin can promote hybridoma cell growth and replace animal derived transferrin.

[0115] The same analysis was carried out with another hybridoma cell line, L243. As can be seen in Table 2. LACROMIN™ (rhLF) can promote cell growth as well as human transferrin (TF). L243 is also an IgG producing cell line. Samples were taken for IgG production. In medium containing LACROMIN™, more IgG is produced than in medium containing transferrin.

Table 2. Effect of human transferrin (TF) and recombinant human lactoferrin (rhLF) on hybridoma growth and monoclonal antibody production.

Treatment	TF/rhLF (ug/ml)	Cell count ($\times 10^6$)		IgG level (ug/ml)	
		Mean	SD	Mean	SD
Control	0	0.39	0.18	15.78	5.63
TF	5	0.70	0.25	34.10	8.44
rhLF	5	0.63	0.10	43.58	8.24
TF	25	0.78	0.24	31.93	7.10
rhLF	25	0.81	0.20	36.10	7.54
TF	100	0.86	0.33	28.58	5.82
rhLF	100	0.78	0.26	29.73	4.28
5% FBS	0	0.98	0.12	23.88	5.50

Example 7: Purification and characterization of recombinant human serum albumin

[0116] To purify rHSA from rice grain, rice grain expressing rHSA was dehusked, ground to flour and mixed for 30 min. with rHSA extraction buffer (Sodium Acetate, pH 4.9). After clarification by filtration, the filtrate was loaded onto an anion-exchange column (Q-Sepharose; GE Healthcare) at a rate of approximately 150 cm/hr. Once loaded, the resin was then washed with equilibration buffer to remove any unbound protein. The eluted rHSA is approximately 90% pure as analyzed by SDS-PAGE. Blue-Sepharose (GE Healthcare) can then be used to increase the purity from 90% to approximately 98% based on scanning analysis of SDS-PAGE gels. The rHSA is then concentrated and desalted via ultrafiltration prior to freeze drying.

[0117] Purified rHSA was subjected to a range of biochemical and biophysical characterizations for comparison to pHSA (Plasma-derived HSA) (Table 3). These tests indicate that rHSA expressed in rice is equivalent to pHSA.

Table 3. Properties of rHSA as compared to pHSA

Property	pHSA	rHSA
N-terminal sequence	DAHKSE	DAHKSE
Glycosylation	None	None
SDS-PAGE/Western	~66 kDa	~66 kDa
Molecular mass (MALDI)	66.9-68.1 kDa	66.8-67.9 kDa
Isoelectric focusing point	pI 5.3	pI 5.3
Ligand binding	Yes	Yes
Thermal stability	Midpoint 65°C	Midpoint 65°C
Esterase activity	Yes	Yes
Protease sensitivity	Same as each other	Same as each other

Example 8: Cell culture media supplemented with recombinant human serum albumin promotes hybridoma cell growth in reduced -serum media.

[0118] The effectiveness of recombinant human serum albumin from rice (rHSA) to stimulate cell growth similar to plasma derived human serum albumin (pHSA) was tested. Basal medium DMEM supplemented with 10 µg/ml insulin, 5.5 µg/ml transferrin, 6.7 ng/ml sodium selenite, 0.20 mg/ml ethanolamine and 2 mM Glutamax (Gibco) was used as common medium (CM). Hybridoma AE1 stocks in CM + 10% fetal bovine serum (FBS), were divided into four lineages: 1) CM +10% FBS as positive control 2) CM without HSA as negative control 3) CM + 100 mg/L rHSA as experimental, and 4) CM +100mg/L plasma-derived HSA (pHSA) as comparative control. Each lineage was then gradually adapted to 1% FBS (reduced serum) by sequential passage of 1×10^5 cell/ml into medium containing 50% reduced FBS. At 1% FBS, each lineage was subsequently passaged 10 times to allow for full adaptation to growth under reduced-serum (1% FBS) conditions. Figure 23 shows cell growth curves of the 4 lineages during the 10th passage under CM +1%FBS. It was found that AE1 hybridoma cells grew much faster and reached a higher density in CM rHSA than in CM without any HSA (Figure 23). It was also found that cells grown in media with rHSA supplementation grew equivalently or better than cells grown in media with plasma derived HSA. This result indicates that rHSA from rice is functionally equivalent to pHSA in enhancing hybridoma cell growth in reduced-serum media.

Example 9: Cell culture media supplemented with recombinant human serum albumin promotes hybridoma cell growth in serum-free media.

[0119] In order to demonstrate that plant derived recombinant human serum albumin functions equivalently to albumin derived from animals to support cell growth, the growth of AE1 hybridoma cells in supplemented serum-free media (SFM) was tested. SFM was prepared that was supplemented with either recombinant human serum albumin or plasma derived human serum albumin at similar concentrations (100 mg/L). SFM without supplemental albumin was prepared as a negative control. This approach allows for direct comparison between plant derived recombinant human serum albumin (CELLASTIM™) and plasma derived human serum albumin in promoting cell growth. SFM consisted of DMEM/F12 basal media supplemented with 10 µg/ml insulin, 5.5 µg/ml transferrin, 6.7 ng/ml sodium selenite, 0.20 mg/ml ethanolamine and 2 mM Glutamax (Gibco). To reach serum-free growth conditions, AE1 Hybridoma cells (ATCC # HB-72) were first adapted to SFM without FBS by a serial adaptation procedure. Briefly, AE1 grown in SFM/10% FBS supplemented with recombinant human serum albumin or plasma derived human serum albumin or no HSA, were successively sub-cultured at 1×10^5 cells/ml into SFM with 50% reduced serum from the previous culture. The SFM/0.25% FBS cultures were subcultured directly into SFM without FBS. Six successive subcultures followed in SFM to allow cells to fully adapt to the respective SFM without FBS.

[0120] AE1 hybridoma cells grown for 6 passages in SFM containing 100 mg/L recombinant human serum albumin or 100 mg/L plasma derived human serum albumin or no HSA were sub-cultured 6-well plates at 1×10^5 cells/ml. The number of viable cells and percent viability was determined daily to examine growth kinetics of the cultures. The subcultures were performed in duplicate to ensure an accurate viable cell count and analysis. Figure 24 shows that AE1 hybridoma cell grew faster and that the maximum number of viable cells was higher in medium supplemented with plant derived recombinant human serum albumin and equivalent to that of plasma derived human serum albumin. Thus, this example shows that plant derived recombinant human serum albumin can promote cell growth in serum-free media and replace animal derived albumin for use in tissue culture.

[0121] The invention now being fully described, it will be apparent to one of ordinary skill in the art that many changes and modifications can be made thereto without departing from the spirit or scope of the appended claims.

IN THE CLAIMS:

1. A cell culture media, comprising at least one plant-produced heterologous protein as a cell culture media component.
2. The cell culture media of claim 1, wherein the plant is a monocot plant.
3. The cell culture media of claim 2, wherein the monocot plant is rice, barley, wheat, rye, corn, millet, triticale, or sorghum.
4. The cell culture media of claim 3, wherein the monocot plant is rice.
5. The cell culture media of claim 1, wherein the plant is a dicot plant.
6. The cell culture media of claim 1, wherein the heterologous protein is a plant protein.
7. The cell culture media of claim 1, wherein the heterologous protein is a non-plant protein.
8. The cell culture media of claim 7, wherein the non-plant protein is an animal protein.
9. The cell culture media of claim 7, wherein the non-plant protein is a human protein.
10. The cell culture media of claim 1, wherein the protein is selected from the group consisting of growth factors, lactoferrin, transferrin, serum albumin, insulin, growth hormone, and fractions thereof, fibronectin attachment factor, lamin attachment factor, collagenase, platelet derived growth factor, brain-derived neutrophic factor, glial-derived neurotrophic factor, thymic factors, haptocorin, lactahedrin, lactoperoxidase, alpha-fetoprotein, immunoglobulin, or alpha-lactalbumin.

11. The cell culture media of claim 10, wherein the growth factors are epidermal growth factors, keratinocyte growth factors, insulin-like growth factors, intestinal trefoil factors, transforming growth factors, granulocyte colony-stimulating factors, nerve growth factors, fibroblast growth factors, or biologically active fragments thereof.
12. The cell culture media of claim 1, wherein the cell culture media is a reduced serum, serum-free medium, or chemically defined media.
13. The cell culture media of claim 1, wherein the cell culture media is a complete media, basal media, or basal media supplemented with a cell culture media component.
14. A method for producing an enhanced cell culture media, comprising producing at least one heterologous protein in a plant cell and combining the at least one plant-produced heterologous protein with a cell culture media.
15. A cell culture media produced by a process comprising producing at least one heterologous protein in a plant cell and combining the at least one plant-produced heterologous protein with a cell culture media.
16. In a cell culture media having one or more proteinaceous cell culture media components, the improvement comprising at least one plant-produced heterologous protein as a cell culture media component, wherein the heterologous protein is produced by the following process:
 - a) transforming a plant cell with a chimeric gene comprising:
 - (i) a promoter from the gene of a seed storage protein;
 - (ii) a first DNA sequence, operably linked to the promoter, encoding a signal sequence of a seed storage protein, and
 - (iii) a second DNA sequence, operably linked to the promoter, encoding the heterologous protein, wherein the first and second DNA sequences are linked in translation frame and together encode a fusion protein comprising the storage protein and the heterologous protein; and

b) growing a plant from the transformed plant cell for a time sufficient to produce seeds containing the heterologous protein.

17. The method of claim 17, further comprising purifying the heterologous protein from the harvested seeds.

18. The method of claim 17, wherein the heterologous protein constitutes at least about 3.0% of the total soluble protein in the harvested seeds.

19. A method for producing a cell culture media having at least one plant-produced heterologous protein as a cell culture media component, the method comprising:

a) transforming a plant cell with a chimeric gene comprising:

(i) a promoter from the gene of a seed storage protein;

(ii) a first DNA sequence, operably linked to the promoter, encoding a signal sequence of a seed storage protein, and

(iii) a second DNA sequence, operably linked to the promoter, encoding the heterologous protein, wherein the first and second DNA sequences are linked in translation frame and together encode a fusion protein comprising the storage protein and the heterologous protein;

b) growing a plant from the transformed plant cell for a time sufficient to produce seeds containing the heterologous protein;

c) harvesting the seeds from the plant; and

d) combining the heterologous protein with a cell culture media.

Sequence Range Egfactor: 4 to 165

Egfactor	AAC N	TCC S	GAC D	TCG S	GAG E	TGC C	CCC P	CTC L	TCC S	CAC H	GAC D	GGT G	TAC Y	TGC C	CTC L	CAC H	GAC D	GGG G>
Native Gene	AAT	GGT	GAC	TCT	GAA	TGT	CCC	CTG	TCC	CAC	GAT	GGG	TAC	TGC	CTC	CAT	GAT	GGT
Egfactor	AAC	TCC	GAC	TCG	GAG	TGC	CCC	CTC	TCC	CAC	GAC	GGT	TAC	TGC	CTC	CAC	GAC	GGG
Egfactor	GTC V	TGC C	ATG M	TAC Y	ATC I	GAG E	GCC A	CTC L	GAC D	AAG K	TAC Y	GCC A	TGC C	AAC N	TGC C	GTC V	GTG V	GGC G>
Native Gene	GTG	TGC	ATG	TAT	ATT	GAA	GCA	TTG	GAC	AAG	TAT	GCA	TGC	AAC	TGT	GTT	GTT	GGC
Egfactor	GTC	TGC	ATG	TAC	ATC	GAG	GCC	CTC	GAC	AAG	TAC	GCC	TGC	AAC	TGC	GTC	GTG	GGC
Egfactor	TAC Y	ATC I	GGC G	GAG E	CGG R	TGC C	CAG Q	TAC Y	CGC R	GAC D	CTC L	AAG K	TGG W	TGG W	GAG E	CTG L	CGC R	TGA >
Native Gene	TAC	ATC	GGG	GAG	CGA	TGT	CAG	TAC	CGA	GAC	CTG	AAG	TGG	TGG	GAA	CTG	CGC	
Egfactor	TAC	ATC	GGC	GAG	CGG	TGC	CAG	TAC	CGC	GAC	CTC	AAG	TGG	TGG	GAG	CTG	CGC	TGA

Epidermal Growth Factor

Number of codons in mature peptide:	53
Number of codons changed:	27 (51%)
Number of nucleotides changed:	30 (19%)

Figure 2. Plasmid map of pAPI303 containing a chimeric gene for expressing human EGF under the control of the rice glutelin promoter in transgenic rice seeds.




Figure 3. Plasmid map of pAPI270 containing a chimeric gene for expressing human EGF under the control of the rice globulin promoter in transgenic rice seeds.




Figure 4. Western blot analysis of recombinant human epidermal growth factor (EGF) expressed in transgenic rice seeds.




Figure 5. Comparison of Codon-optimized (Insgfact) and Native Genes for the Insulin-like Growth Factor (IGF)

Sequence Range of Insgfact: 4 to 216

Insgfact	10	20	30	40	50	60	70	
	GGC CCA GAG ACC CTG TGC GGT GCG GAG CTG GTG GAC GCC CTC CAG TTC GTC TGC GGG GAC CGG GGC TTC TAC TTC							
	G P E T L C G A E L V D A L Q F V C G D R G F Y . P>							
native gene	320	330	340	350	360	370	380	
	GGA CCG GAG ACG CTC TGC GGG GCT GAG CTG GTG GAT GCT CTT CAG TTC GTG TGT GGA GAC AGG GGC TTT TAT TTC>							
Insgfact	GGC CCA GAG ACC CTG TGC GGT GCG GAG CTG GTG GAC GCC CTC CAG TTC GTC TGC GGG GAC CGG GGC TTC TAC TTC							
Insgfact	80	90	100	110	120	130	140	150
	AAC AAG CCA ACG GGC TAC GGG TCC TCC TCG CGC CGC GCC CCC CAG ACC GGC ATC GTG GAC GAG TGC TGC TTC CGC							
	N K P T G Y G S S S R R A P Q T G I V D E C C F R>							
native gene	390	400	410	420	430	440	450	460
	AAC AAG CCC ACA GGG TAT GGC TCC AGC AGT CGG AGG GCG CCT CAG ACA GGC ATC GTG GAT GAG TGC TGC TTC CGG>							
Insgfact	AAC AAG CCA ACG GGC TAC GGG TCC TCC TCG CGC CGC GCC CCC CAG ACC GGC ATC GTG GAC GAG TGC TGC TTC CGC							
Insgfact	160	170	180	190	200	210		
	TCC TGC GAC CTC CGG CGG CTG GAG ATG TAC TGC GCC CCA CTC AAG CCC GCC AAG AGC GCC TGA							
	S C D L R R L E M Y C A P L K P A K S A *>							
native gene	470	480	490	500	510	520		
	AGC TGT GAT CTA AGG AGG CTG GAG ATG TAT TGC GCA CCC CTC AAG CCT GCC AAG TCA GCT>							
Insgfact	TCC TGC GAC CTC CGG CGG CTG GAG ATG TAC TGC GCC CCA CTC AAG CCC GCC AAG AGC GCC							

Insulin-like Growth Factor

Number of codons in mature peptide: 70

Number of codons changed: 40 (57%)

Number of nucleotides changed: 47 (22%)

Figure 6. Plasmid map of pAPI271 containing a chimeric gene for expressing human IGF-1 under the control of the rice globulin promoter in transgenic rice seeds.




Figure 7. Plasmid map of pAPI304 containing a chimeric gene for expressing human IGF-1 under the control of the rice glutelin promoter in transgenic rice seeds.




Figure 8. Western blot analysis of recombinant human insulin-like growth factor (IGF-1) expressed in transgenic rice seeds.




Figure 9. Comparison of Codon-optimized (Trefoil) and Native Genes for the Human Trefoil Peptide

Sequence Range of Trefoil: 6 to 188

Trefoil	10	20	30	40	50	60	70	80
	GAG GAG TAC GTC GGG CTC TCC GCT AAC CAA TGC GCG GTC CCG GCC AAG GAC CGG GTG GAC TGC GGC TAC CCC CAC							
	E E Y V G L S A N Q C A V P A K D R V D C G Y P H>							
nativegene	50	60	70	80	90	100	110	
	GAG GAG TAC GTG GGC CTG TCT GCA AAC CAG TGT GCC GTG CCG GCC AAG GAC AGG GTG GAC TGC GGC TAC CCC CAT>							
Trefoil	GAG GAG TAC GTC GGG CTC TCC GCT AAC CAA TGC GCG GTC CCG GCC AAG GAC CGG GTG GAC TGC GGC TAC CCC CAC							
Trefoil	90	100	110	120	130	140	150	
	GTG ACG CCG AAG GAG TGC AAC AAC CGG GGC TGC TGC TTC GAC TCC CGC ATC CCA GGC GTG CCG TGG TGC TTC AAG							
	V T P K E C N N R G C C F D S R I P G V P W C F K>							
nativegene	120	130	140	150	160	170	180	190
	GTC ACC CCC AAG GAG TGC AAC AAC CGG GGC TGC TGC TTC GAC TCC AGG ATC CCT GGA GTG CCT TGG TGT TTC AAG>							
Trefoil	GTG ACG CCG AAG GAG TGC AAC AAC CGG GGC TGC TGC TTC GAC TCC CGC ATC CCA GGC GTG CCG TGG TGC TTC AAG							
Trefoil	160	170	180					
	CCC CTC ACC CGC AAG ACG GAG TGC ACG TTC TGA							
	P L T R K T E C T F *>							
nativegene	200	210	220					
	CCC CTG ACT AGG AAG ACA GAA TGC ACC TTC TGA>							
Trefoil	CCC CTC ACC CGC AAG ACG GAG TGC ACG TTC TGA							

Human Trefoil Peptide

Number of codons in mature peptide: 60

Number of codons changed: 26 (43%)

Number of nucleotides changed: 28 (15%)

Figure 10. Plasmid map of pAPI269 containing a chimeric gene for expressing human ITF under the control of the rice globulin promoter in transgenic rice seeds.




Figure 11. Plasmid map of pAPI307 containing a chimeric gene for expressing human ITF under the control of the rice glutelin promoter in transgenic rice seeds.




Figure 12. Western blot analysis of recombinant human intestinal trefoil factor (ITF) expressed in transgenic rice seeds.




Figure 13. Codon-optimized Human Lactoferrin Gene and its Alignment to its Native Form

native lac	GGC	CGT	AGG	AGA	AGG	AGT	GTT	CAG	TGG	TGC	GCC	GTA	TCC	CAA	CCC	GAG	GCC	ACA	AAA	TGC	TTC	CAA	TGG	CAA	AGG
	G	R	R	R	R	S	V	Q	W	C	A	V	S	Q	P	E	A	T	K	C	F	Q	W	Q	R
cod opt lac	GGG	CGG	CGG	CGG	CGC	TCG	GTG	CAG	TGG	TGC	GCC	GTG	TCC	CAG	CCC	GAG	GCG	ACC	AAG	TGC	TTC	CAG	TGG	CAG	CGC
native lac	GGC	CGT	AGG	AGA	AGG	AGT	GTT	CAG	TGG	TGC	GCC	GTA	TCC	CAA	CCC	GAG	GCC	ACA	AAA	TGC	TTC	CAA	TGG	CAA	AGG
native lac	AAT	ATG	AGA	AAA	GTG	CGT	GGC	CCT	CCT	GTC	AGC	TGC	ATA	AAG	AGA	GAC	TCC	CCC	ATC	CAG	TGT	ATC	CAG	GCC	ATT
	N	M	R	K	V	R	G	P	P	V	S	C	I	K	R	D	S	P	I	Q	C	I	Q	A	I
cod opt lac	AAC	ATG	CGG	AAG	GTG	CGC	GGC	CCG	CCG	GTC	AGC	TGC	ATC	AAG	CGG	GAC	TCC	CCC	ATC	CAA	TGC	ATC	CAG	GCC	ATC
native lac	AAT	ATG	AGA	AAA	GTG	CGT	GGC	CCT	CCT	GTC	AGC	TGC	ATA	AAG	AGA	GAC	TCC	CCC	ATC	CAG	TGT	ATC	CAG	GCC	ATT
native lac	GCG	GAA	AAC	AGG	GCC	GAT	GCT	GTG	ACC	CTT	GAT	GGT	GGT	TTC	ATA	TAC	GAG	GCA	GGC	CTG	GCC	CCC	TAC	AAA	CTG
	A	E	N	R	A	D	A	V	T	L	D	G	G	F	I	Y	E	A	G	L	A	P	Y	K	L
cod opt lac	GCG	GAG	AAC	CGC	GCC	GAC	GCG	GTC	ACC	CTG	GAC	GGC	GGG	TTC	ATC	TAC	GAG	GCG	GGG	CTC	GCC	CCG	TAC	AAG	CTC
native lac	GCG	GAA	AAC	AGG	GCC	GAT	GCT	GTG	ACC	CTT	GAT	GGT	GGT	TTC	ATA	TAC	GAG	GCA	GGC	CTG	GCC	CCC	TAC	AAA	CTG
native lac	CGA	CCT	GTA	GCG	GCG	GAA	GTC	TAC	GGG	ACC	GAA	AGA	CAG	CCA	CGA	ACT	CAC	TAT	TAT	GCC	GTG	GCT	GTG	GTG	AAG
	R	P	V	A	A	E	V	Y	G	T	E	R	Q	P	R	T	H	Y	Y	A	V	A	V	V	K
cod opt lac	CGC	CCG	GTG	GCG	GCG	GAG	GTG	TAC	GGC	ACC	GAG	CGC	CAG	CCG	CGC	ACG	CAC	TAC	TAC	GCG	GTG	GCC	GTC	GTC	AAG
native lac	CGA	CCT	GTA	GCG	GCG	GAA	GTC	TAC	GGG	ACC	GAA	AGA	CAG	CCA	CGA	ACT	CAC	TAT	TAT	GCC	GTG	GCT	GTG	GTG	AAG
native lac	AAG	GGC	GGC	AGC	TTT	CAG	CTG	AAC	GAA	CTG	CAA	GGT	CTG	AAG	TCC	TGC	CAC	ACA	GGC	CTT	CGC	AGG	ACC	GCT	GGA
	K	G	G	S	F	Q	L	N	E	L	Q	G	L	K	S	C	H	T	G	L	R	R	T	A	G
cod opt lac	AAG	GGC	GGG	TCC	TTC	CAG	CTC	AAC	GAG	CTG	CAG	GGC	CTG	AAG	TCC	TGC	CAC	ACG	GGC	CTC	CGG	CGG	ACG	GCG	GGC
native lac	AAG	GGC	GGC	AGC	TTT	CAG	CTG	AAC	GAA	CTG	CAA	GGT	CTG	AAG	TCC	TGC	CAC	ACA	GGC	CTT	CGC	AGG	ACC	GCT	GGA

native lac	380	TGG AAT GTC CCT	390	ATA GGG ACA CTT CGT	400	CCA TTC TTG AAT TGG	410	ACG GGT CCA CCT GAG	420	CCC ATT GAG GCA GCT	430	440	450
		W N V P I G T L R P F L N W T G P P E P I E A A V											
cod opt lac	380	TGG AAC GTG CCC	390	ATC GGC ACC CTG CGC	400	CCC TTC CTG AAC TGG	410	ACC GGC CCG CCG GAG	420	CCG ATC GAG GCC GCC	430	440	450
native lac		TGG AAT GTC CCT		ATA GGG ACA CTT CGT		CCA TTC TTG AAT TGG		ACG GGT CCA CCT GAG		CCC ATT GAG GCC GCT			
native lac	460	GCC AGG TTC TTC	470	TCA GCC AGC TGT GTT	480	CCC GGT GCA GAT AAA	490	GGA CAG TTC CCC AAC	500	CTG TGT CGC CTG TGT	510	520	
		A R F F S A S C V P G A D K G Q F P N L C R L C A											
cod opt lac	460	GCC CGC TTC TTC	470	AGC GCC TCC TGC GTC	480	CCC GGC GCC GAC AAG	490	GGC CAG TTC CCG AAC	500	CTC TGC CGG CTC TGC	510	520	
native lac		GCC AGG TTC TTC		TCA GCC AGC TGT GTT		CCC GGT GCA GAT AAA		GGG CAG TTC CCC AAC		CTG TGT CGC CTG TGT			
native lac	530	GGG ACA GGG GAA	540	AAC AAA TGT GCC TTC	550	TCC TCC CAG GAA CCG	560	570	580	590	600		
		G T G E N K C A F S S Q E P Y F S Y S G A F K C L											
cod opt lac	530	GGG ACG GGC GAG	540	AAC AAG TGC GCC TTC	550	TCC TCG CAG GAG CCG	560	570	580	590	600		
native lac		GGG ACA GGG GAA		AAC AAA TGT GCC TTC		TCC TCG CAG GAA CCG		TAC TTC TCC TAC TCG		GGC GCG TTC AAG TGC			
native lac	610	AGA GAC GGG GCT	620	GGA GAC GTG GCT TTT	630	ATC AGA GAG AGC ACA	640	GTG TTT GAG GAC CTG	650	TCA GAC GAG GCT GAA	660	670	
		R D G A G D V A F I R E S T V F E D L S D E A E R											
cod opt lac	610	CGC GAC GGG GCC	620	GGC GAC GTG GCG TTC	630	ATC CGC GAG TCC ACC	640	GTG TTC GAG GAC CTC	650	TCC GAC GAG GCG GAG	660	670	
native lac		AGA GAC GGG GCT		GGA GAC GTG GCT TTT		ATC AGA GAG AGC ACA		GTG TTT GAG GAC CTG		TCA GAC GAG GCT GAA			
native lac	680	GAC GAG TAT GAG	690	TTA CTC TGC CCA GAC	700	AAC ACT CGG AAG CCA	710	GTG GAC AAG TTC AAA	720	GAC TGC CAT CTG GCC	730	740	750
		D E Y E L L C P D N T R K P V D K F K D C H L A R											
cod opt lac	680	GAC GAG TAC GAG	690	CTG CTG TGC CCC GAC	700	AAC ACC CGC AAG CCG	710	GTG GAC AAG TTC AAG	720	GAC TGC CAC CTG GCG	730	740	750
native lac		GAC GAG TAT GAG		TTA CTC TGC CCA GAC		AAC ACT CGG AAG CCA		GTG GAC AAG TTC AAA		GAC TGC CAT CTG GCC			
native lac	760	GTC CCT TCT CAT	770	GCC GTT GTG GCA CGA	780	AGT GTG AAT GGC AAG	790	GAG GAT GCC ATC TGG	800	810	820		
		V P S H A V V A R S V N G K E D A I W N L L R Q A											
cod opt lac	760	GTG CCC TCG CAC	770	GCG GTC GTC GCC CGC	780	AGC GTC AAC GGC AAG	790	GAG GAC GCG ATC TGG	800	AAC CTC CTC CGC	810	820	
native lac		GTG CCT TCT CAT		GCC GTT GTG GCA CGA		AGT GTG AAT GGC AAG		GAG GAT GCC ATC TGG		AAC CTC CTC CGC			

native lac	830	840	850	860	870	880	890	900
	CAG GAA AAG TTT	GGA AAG GAC AAG TCA	CCG AAA TTC CAG CTC	TTT GGC TCC CCT AGT	GGG CAG AAA GAT CTG	CTG		
	Q E K F	G K D K S P	K F Q L F	G S P S G	Q K D L L			
cod opt lac	830	840	850	860	870	880	890	900
	CAG GAG AAG TTC	GGC AAG GAC AAG TCC	CCC AAG TTC CAG CTC	TTT GGC AGC CCC AGC	GGC CAG AAG GAC CTC	CTC		
native lac	CAG GAA AAG TTT	GGA AAG GAC AAG TCA	CCG AAA TTC CAG CTC	TTT GGC TCC CCT AGT	GGG CAG AAA GAT CTG	CTG		
native lac	910	920	930	940	950	960	970	
	TTC AAG GAC TCT GCC	ATT GGG TTT TCG	AGG GTG CCC CCG	AGG ATA GAT TCT	GGG CTG TAC CTT	GGC TCC GGC	TAC	
	F K D S A I G F S R V P P R I D S G L Y L G S G Y							
cod opt lac	910	920	930	940	950	960	970	
	TTC AAG GAC TCC	GCG ATC GGC TTC	TCC CGC GTG CCC	CCG CGC ATC GAC	TCC GGC CTG TAC	CTC GGC TCC	GGG TAC	
native lac	TTC AAG GAC TCT	GCC ATT GGG TTT	TCG AGG GTG CCC	CCG AGG ATA GAT	TCT GGG CTG TAC	CTT GGC TCC	GGC TAC	
native lac	980	990	1000	1010	1020	1030	1040	1050
	TTC ACT GCC ATC	CAG AAC TTG	AGG AAA AGT	GAG GAG GAA GTG	GCT GCC CGG	CGT GCG CGG	GTC GTG TGG	TGT GCG
	F T A I Q N L R K S E E V A R R A R V W C A							
cod opt lac	980	990	1000	1010	1020	1030	1040	1050
	TTC ACC GCG ATC	CAG AAC CTC	CGG AAG AGC	GAG GAG GAG GTG	GCG GCG CGG	CGG GCC CGC	GTC GTG TGG	TGC GCC
native lac	TTC ACT GCC ATC	CAG AAC TTG	AGG AAA AGT	GAG GAG GAA GTG	GCT GCC CGG	CGT GCG CGG	GTC GTG TGG	TGT GCG
native lac	1060	1070	1080	1090	1100	1110	1120	
	GTG GGC GAG CAG	GAG CTG CGC	AAG TGT AAC	CAG TGG AGT	GGC TTG AGC	GAA GGC AGC	GTG ACC	TGC TCC
	V G E Q L R K C N Q W S G L S E G S V T C S S A							
cod opt lac	1060	1070	1080	1090	1100	1110	1120	
	GTG GGC GAG CAG	GAG CTG CGG	AAG TGC AAC	CAG TGG AGC	GGC CTG AGC	GAG GGC TCG	GTG ACC	TGC TCC
native lac	GTG GGC GAG CAG	GAG CTG CGC	AAG TGT AAC	CAG TGG AGT	GGC TTG AGC	GAA GGC AGC	GTG ACC	TGC TCC
native lac	1130	1140	1150	1160	1170	1180	1190	1200
	TCC ACC ACA GAG	GAC TGC ATC	GCC CTG GTG	CTG AAA GGA	GAA GCT GAT	GCC ATG	AGT TTG	GAT GAA
	S T T E D C I A L V L K G E A D A M S L D E G Y V							
cod opt lac	1130	1140	1150	1160	1170	1180	1190	1200
	AGC ACC ACC GAG	GAC TGC ATC	GCG CTC GTC	CTC AAG GGG	GAG GCC GAC	GCG ATG	AGC CTC	GAC GGG
native lac	TCC ACC ACA GAG	GAC TGC ATC	GCC CTG GTG	CTG AAA GGA	GAA GCT GAT	GCC ATG	AGT TTG	GAT GAA
native lac	1210	1220	1230	1240	1250	1260	1270	
	TAC ACT GCA GGC	AAA TGT GGT	TTG GTG CCT	GTC CTG GCA	GAG AAC TAC	AAA TCC	CAA CAA	AGC AGT
	Y T A G K C G L V P V L A E N Y K S Q Q S S D P D							
cod opt lac	1210	1220	1230	1240	1250	1260	1270	
	TAC ACC GCC GGC	AAG TGC GGC	CTG GTC CCG	GTC CTG GCG	GAG AAC TAC	AAG TCG	CAG CAG	TCC AGC
native lac	TAC ACT GCA GGC	AAA TGT GGT	TTG GTG CCT	GTC CTG GCA	GAG AAC TAC	AAA TCC	CAA CAA	AGC AGT

		1280			1290			1300			1310			1320			1330			1340			1350			
native	lac	CCT	AAC	TGT	GTG	GAT	AGA	CCT	GTG	GAA	GGA	TAT	CTT	GCT	GTG	GCG	GTG	GTT	AGG	AGA	TCA	GAC	ACT	AGC	CTT	ACC
		P	N	C	V	D	R	P	V	E	G	Y	L	A	V	A	V	V	R	R	S	D	T	S	L	T
cod opt	lac	1280			1290			1300			1310			1320			1330			1340			1350			
		CCG	AAC	TGC	GTG	GAC	CGC	CCC	GTC	GAG	GGC	TAC	CTC	GCC	GTG	GCC	GTC	GTG	CGC	CGG	TCC	GAC	ACC	TCC	CTG	ACG
native	lac	CCT	AAC	TGT	GTG	GAT	AGA	CCT	GTG	GAA	GGA	TAT	CTT	GCT	GTG	GCG	GTG	GTT	AGG	AGA	TCA	GAC	ACT	AGC	CTT	ACC
		1360			1370			1380			1390			1400			1410			1420						
native	lac	TGG	AAC	TCT	GTG	AAA	GGC	AAG	AAG	TCC	TGC	CAC	ACC	GCC	GTG	GAC	AGG	ACT	GCA	GGC	TGG	AAT	ATC	CCC	ATG	GGC
		W	N	S	V	K	G	K	K	S	C	H	T	A	V	D	R	T	A	G	W	N	I	P	M	G
cod opt	lac	1360			1370			1380			1390			1400			1410			1420						
		TGG	AAC	AGC	GTG	AAG	GGC	AAG	AAG	AGC	TGC	CAC	ACC	GCC	GTG	GAC	CGC	ACC	GCC	GGC	TGG	AAC	ATC	CCG	ATG	GGC
native	lac	TGG	AAC	TCT	GTG	AAA	GGC	AAG	AAG	TCC	TGC	CAC	ACC	GCC	GTG	GAC	AGG	ACT	GCA	GGC	TGG	AAT	ATC	CCC	ATG	GGC
		1430			1440			1450			1460			1470			1480			1490			1500			
native	lac	CTG	CTC	TTC	AAC	CAG	ACG	GGC	TCC	TGC	AAA	TTT	GAT	GAA	TAT	TTC	AGT	CAA	AGC	TGT	GCC	CCT	GGG	TCT	GAC	CCG
		L	L	F	N	Q	T	G	S	C	K	F	D	E	Y	F	S	Q	S	C	A	P	G	S	D	P
cod opt	lac	1430			1440			1450			1460			1470			1480			1490			1500			
		CTC	CTC	TTC	AAC	CAG	ACC	GGC	TCC	TGC	AAG	TTT	GAC	GAG	TAC	TTC	TCC	CAG	TCC	TGC	GCC	CCC	GGC	TGC	GAC	CCC
native	lac	CTG	CTC	TTC	AAC	CAG	ACG	GGC	TCC	TGC	AAA	TTT	GAT	GAA	TAT	TTC	AGT	CAA	AGC	TGT	GCC	CCT	GGG	TCT	GAC	CCG
		1510			1520			1530			1540			1550			1560			1570						
native	lac	AGA	TCT	AAT	CTC	TGT	GCT	CTG	TGT	ATT	GGC	GAC	GAG	CAG	GGT	GAG	AAT	AAG	TGC	GTG	CCC	AAC	AGC	AAC	GAG	AGA
		R	S	N	L	C	A	L	C	I	G	D	E	Q	G	E	N	K	C	V	P	N	S	N	E	R
cod opt	lac	1510			1520			1530			1540			1550			1560			1570						
		CGC	TCC	AAC	CTG	TGC	GCC	CTC	TGC	ATC	GGG	GAC	GAG	CAG	GGC	GAG	AAC	AAG	TGC	GTG	CCC	AAC	AGC	AAC	GAG	CGG
native	lac	AGA	TCT	AAT	CTC	TGT	GCT	CTG	TGT	ATT	GGC	GAC	GAG	CAG	GGT	GAG	AAT	AAG	TGC	GTG	CCC	AAC	AGC	AAC	GAG	AGA
		1580			1590			1600			1610			1620			1630			1640			1650			
native	lac	TAC	TAC	GGC	TAC	ACT	GGG	GCT	TTC	CGG	TGC	CTG	GCT	GAG	AAT	GCT	GGA	GAC	GTT	GCA	TTT	GTG	AAA	GAT	GTC	ACT
		Y	Y	G	Y	T	G	A	F	R	C	L	A	E	N	A	G	D	V	A	F	V	K	D	V	T
cod opt	lac	1580			1590			1600			1610			1620			1630			1640			1650			
		TAC	TAC	GGC	TAC																					

native lac	1730 TGC CTC C L	1740 GAT GGC AAA D G K	1750 CGG AAG CCT GTG R K P V	1760 ACT GAG GCT T E A	1770 AGA AGC TGC R S C	1780 CAT CTT GCC ATG H L A M	1790 GCC AAT CAT GCC P N H A	1800 GTG V
cod opt lac	1730 TGC CTC 	1740 GAC GGC AAG 	1750 CGC AAG CCC GTG 	1760 ACC GAG GCG 	1770 CGG TCC TGC 	1780 CAC CTG GCG ATG 	1790 GCC AAT CAC GCC 	1800 GTC
native lac	1730 TGC CTC 	1740 GAT GGC AAA 	1750 CGG AAG CCT GTG 	1760 ACT GAG GCT 	1770 AGA AGC TGC 	1780 CAT CTT GCC ATG 	1790 GCC AAT CAT GCC 	1800 GTC
native lac	1810 GTG TCT V S	1820 CGG ATG GAT AAG R M D K	1830 GAA CGC CTG AAA E R L K	1840 CAG GTG TTG Q V L	1850 CTC CAC CAA L H Q	1860 CAG GCT AAA Q A K	1870 TTT GGG AGA F G R	1880 AAT GGA N A G
cod opt lac	1810 GTC TCC 	1820 CGC ATG GAC AAG 	1830 GAG CGC CTC AAG 	1840 CAG GTG CTC 	1850 CTG CAC CAG 	1860 CAG GCC AAG 	1870 TTC GGC CGG 	1880 AAT GGA
native lac	1810 GTG TCT 	1820 CGG ATG GAT AAG 	1830 GAA CGC CTG AAA 	1840 CAG GTG TTG 	1850 CTC CAC CAA 	1860 CAG GCT AAA 	1870 TTT GGG AGA 	1880 AAT GGA
native lac	1880 TCT GAC S D	1890 TGC CCG GAC AAG C P D K	1900 TTT TGC TTA TTC F C L F	1910 CAG TCT GAA ACC Q S E T	1920 AAA AAC CTT CTG K N L F	1930 TTC AAT GAC AAC N D N T	1940 ACT GAG TGT E C	
cod opt lac	1880 AGC GAC 	1890 TGC CCG GAC AAG 	1900 TTC TGC CTG TTC 	1910 CAG TCG GAG ACC 	1920 AAC AAT CTC CTC 	1930 TTC AAT GAC AAC 	1940 ACC GAG TGC 	1950 TGT
native lac	1880 TCT GAC 	1890 TGC CCG GAC AAG 	1900 TTC TGC CTG TTC 	1910 CAG TCT GAA ACC 	1920 AAC AAT CTC CTC 	1930 TTC AAT GAC AAC 	1940 ACC GAG TGT 	1950 TGT
native lac	1960 CTG GCC L A	1970 AGA CTC CAT GGC R L H G	1980 ACA AAA ACA TAT T K T Y	1990 GAA AAA TAT TTG E K Y L	2000 GGA CCA CAG TAT G P Q Y	2010 GTC GCA GGC ATT V A G I	2020 ACT AAT CTG T N L	
cod opt lac	1960 CTG GCG 	1970 CGC CTC CAC GGC 	1980 AAG ACC ACC TAC 	1990 AAG TAC CTC GGC 	2000 CCG CAG TAC GTC 	2010 GCC GGC ATC ACC 	2020 AAC CTC 	
native lac	1960 CTG GCC 	1970 AGA CTC CAT GGC 	1980 ACA AAA ACA TAT 	1990 GAA AAA TAT TTG 	2000 GGA CCA CAG TAT 	2010 GTC GCA GGC ATT 	2020 ACT AAT CTG 	
native lac	2030 AAA AAG K K	2040 TGC TCA ACC TCC C S T S	2050 CCC CTC CTG GAA P L L E	2060 GCC TGT GAA TTC A C E F	2070 CTC AGG AAG TAA L R K			
cod opt lac	2030 AAG AAG 	2040 TGC TCC ACC TCC 	2050 CCC CTC CTG GAG 	2060 GCC TGT GAG TTC 	2070 CTC CGC AAG TGA 			
native lac	2030 AAA AAG 	2040 TGC TCA ACC TCC 	2050 CCC CTC CTG GAA 	2060 GCC TGT GAA TTC 	2070 CTC AGG AAG TAA 			

2079 = Total number of nucleotides

467 = Number of nucleotides changed

693 = Total Number of codons

413 = Number of codons changed

Figure 14: Plasmid map of pAPI164




Figure 15: Recombinant human lactoferrin expressed in transgenic rice grains




Figure 16. Stable expression of rhLF in transgenic rice grains from R₂ through R₁₀ generations.




Figure 17 DNA and protein sequence of fusion between Gt1 signal peptide (Gt1 SP) and codon-optimized human serum albumin (OPTIMIZED HSA)

```

      10      20      30      40
ATG GCA TCC ATA AAT CGC CCC ATA GTT TTC TTC ACA GTT TGC TTG
M  A  S  I  N  R  P  I  V  F  F  T  V  C  L>
_a_a_a_a_a_a_Gt1 SP_a_a_a_a_a_a_a_>

      50      60      70      80      90
TTC CTC TTG TGC GAT GGC TCC CTA GCC GAC GCC CAC AAG AGC GAG
F  L  L  C  D  G  S  L  A>
_a_a_a_Gt1 SP_a_a_a_a_>
      D  A  H  K  S  E>
      _OPTIMIZED HSA _b_>

     100     110     120     130
GTG GCC CAC CGC TTC AAG GAC CTC GGC GAG GAG AAC TTC AAG GCC
V  A  H  R  F  K  D  L  G  E  E  N  F  K  A>
_b_b_b_b_b_OPTIMIZED HSA _b_b_b_b_b_>

     140     150     160     170     180
CTC GTG CTC ATC GCC TTC GCC CAG TAC CTC CAG CAG TGC CCG TTC
L  V  L  I  A  F  A  Q  Y  L  Q  Q  C  P  F>
_b_b_b_b_b_OPTIMIZED HSA _b_b_b_b_b_>

     190     200     210     220
GAG GAC CAC GTG AAG CTC GTG AAC GAG GTG ACC GAG TTC GCC AAG
E  D  H  V  K  L  V  N  E  V  T  E  F  A  K>
_b_b_b_b_b_OPTIMIZED HSA _b_b_b_b_b_>

     230     240     250     260     270
ACC TGC GTG GCC GAC GAG AGC GCC GAG AAC TGC GAC AAG AGC CTC
T  C  V  A  D  E  S  A  E  N  C  D  K  S  L>
_b_b_b_b_b_OPTIMIZED HSA _b_b_b_b_b_>

     280     290     300     310
CAC ACC CTC TTC GGC GAC AAG CTC TGC ACC GTG GCC ACC CTC CGC
H  T  L  F  G  D  K  L  C  T  V  A  T  L  R>
_b_b_b_b_b_OPTIMIZED HSA _b_b_b_b_b_>

     320     330     340     350     360
GAG ACC TAC GGC GAG ATG GCC GAC TGC TGC GCC AAG CAG GAG CCG
E  T  Y  G  E  M  A  D  C  C  A  K  Q  E  P>
_b_b_b_b_b_OPTIMIZED HSA _b_b_b_b_b_>

     370     380     390     400
GAG CGC AAC GAG TGC TTC CTC CAG CAC AAG GAC GAC AAC CCG AAC
E  R  N  E  C  F  L  Q  H  K  D  D  N  P  N>
_b_b_b_b_b_OPTIMIZED HSA _b_b_b_b_b_>

     410     420     430     440     450
CTC CCG CGC CTC GTG CGC CCG GAG GTG GAC GTG ATG TGC ACC GCC
L  P  R  L  V  R  P  E  V  D  V  M  C  T  A>
_b_b_b_b_b_OPTIMIZED HSA _b_b_b_b_b_>

```

```

      460      470      480      490
TTC CAC GAC AAC GAG GAG ACC TTC CTC AAG AAG TAC CTC TAC GAG
F  H  D  N  E  E  T  F  L  K  K  Y  L  Y  E>
__b__b__b__b__b__OPTIMIZED HSA __b__b__b__b__b__>

      500      510      520      530      540
ATC GCC CGC CGC CAC CCG TAC TTC TAC GCC CCG GAG CTC CTC TTC
I  A  R  R  H  P  Y  F  Y  A  P  E  L  L  F>
__b__b__b__b__b__OPTIMIZED HSA __b__b__b__b__b__>

      550      560      570      580
TTC GCC AAG CGC TAC AAG GCC GCC TTC ACC GAG TGC TGC CAG GCC
F  A  K  R  Y  K  A  A  F  T  E  C  C  Q  A>
__b__b__b__b__b__OPTIMIZED HSA __b__b__b__b__b__>

      590      600      610      620      630
GCC GAC AAG GCC GCC TGC CTC CTC CCG AAG CTC GAC GAG CTC CGC
A  D  K  A  A  C  L  L  P  K  L  D  E  L  R>
__b__b__b__b__b__OPTIMIZED HSA __b__b__b__b__b__>

      640      650      660      670
GAC GAG GGC AAG GCC TCC AGC GCC AAG CAG CGC CTC AAG TGC GCC
D  E  G  K  A  S  S  A  K  Q  R  L  K  C  A>
__b__b__b__b__b__OPTIMIZED HSA __b__b__b__b__b__>

      680      690      700      710      720
AGC CTC CAG AAG TTC GGC GAG CGC GCC TTC AAG GCC TGG GCC GTG
S  L  Q  K  F  G  E  R  A  F  K  A  W  A  V>
__b__b__b__b__b__OPTIMIZED HSA __b__b__b__b__b__>

      730      740      750      760
GCC CGC CTC AGC CAG CGC TTC CCG AAG GCC GAG TTC GCC GAG GTG
A  R  L  S  Q  R  F  P  K  A  E  F  A  E  V>
__b__b__b__b__b__OPTIMIZED HSA __b__b__b__b__b__>

      770      780      790      800      810
TCC AAG CTC GTG ACC GAC CTC ACC AAG GTG CAC ACC GAG TGC TGC
S  K  L  V  T  D  L  T  K  V  H  T  E  C  C>
__b__b__b__b__b__OPTIMIZED HSA __b__b__b__b__b__>

      820      830      840      850
CAC GGC GAC CTC CTG GAG TGC GCC GAC GAC CGC GCC GAC CTC GCC
H  G  D  L  L  E  C  A  D  D  R  A  D  L  A>
__b__b__b__b__b__OPTIMIZED HSA __b__b__b__b__b__>

      860      870      880      890      900
AAG TAC ATC TGC GAG AAC CAG GAC AGC ATC TCC AGC AAG CTC AAG
K  Y  I  C  E  N  Q  D  S  I  S  S  K  L  K>
__b__b__b__b__b__OPTIMIZED HSA __b__b__b__b__b__>

      910      920      930      940
GAG TGC TGC GAG AAG CCG CTC CTG GAG AAG TCC CAC TGC ATC GCC
E  C  C  E  K  P  L  L  E  K  S  H  C  I  A>
__b__b__b__b__b__OPTIMIZED HSA __b__b__b__b__b__>

```

```

      950          960          970          980          990
GAG GTG GAG AAC GAC GAG ATG CCG GCC GAC CTC CCG TCC CTC GCC
E  V  E  N  D  E  M  P  A  D  L  P  S  L  A>
__b__b__b__b__b__OPTIMIZED HSA __b__b__b__b__b__>

      1000         1010         1020         1030
GCC GAC TTC GTG GAG AGC AAG GAC GTG TGC AAG AAC TAC GCC GAG
A  D  F  V  E  S  K  D  V  C  K  N  Y  A  E>
__b__b__b__b__b__OPTIMIZED HSA __b__b__b__b__b__>

      1040         1050         1060         1070         1080
GCC AAG GAC GTC TTC CTC GGC ATG TTC CTC TAC GAG TAC GCC CGC
A  K  D  V  F  L  G  M  F  L  Y  E  Y  A  R>
__b__b__b__b__b__OPTIMIZED HSA __b__b__b__b__b__>

      1090         1100         1110         1120
CGC CAC CCG GAC TAC TCC GTG GTG CTC CTC CTC CGC CTC GCC AAG
R  H  P  D  Y  S  V  V  L  L  L  R  L  A  K>
__b__b__b__b__b__OPTIMIZED HSA __b__b__b__b__b__>

      1130         1140         1150         1160         1170
ACC TAC GAG ACC ACC CTG GAG AAG TGC TGC GCC GCC GCC GAC CCG
T  Y  E  T  T  L  E  K  C  C  A  A  A  D  P>
__b__b__b__b__b__OPTIMIZED HSA __b__b__b__b__b__>

      1180         1190         1200         1210
CAC GAG TGC TAC GCC AAG GTG TTC GAC GAG TTC AAG CCG CTC GTG
H  E  C  Y  A  K  V  F  D  E  F  K  P  L  V>
__b__b__b__b__b__OPTIMIZED HSA __b__b__b__b__b__>

      1220         1230         1240         1250         1260
GAG GAG CCG CAG AAC CTC ATC AAG CAG AAC TGC GAG CTC TTC GAG
E  E  P  Q  N  L  I  K  Q  N  C  E  L  F  E>
__b__b__b__b__b__OPTIMIZED HSA __b__b__b__b__b__>

      1270         1280         1290         1300
CAG CTC GGC GAG TAC AAG TTC CAG AAC GCC CTC CTC GTG CGC TAC
Q  L  G  E  Y  K  F  Q  N  A  L  L  V  R  Y>
__b__b__b__b__b__OPTIMIZED HSA __b__b__b__b__b__>

      1310         1320         1330         1340         1350
ACC AAG AAG GTG CCG CAG GTG TCC ACC CCG ACC CTC GTG GAG GTG
T  K  K  V  P  Q  V  S  T  P  T  L  V  E  V>
__b__b__b__b__b__OPTIMIZED HSA __b__b__b__b__b__>

      1360         1370         1380         1390
TCC CGC AAC CTC GGC AAG GTG GGC AGC AAG TGC TGC AAG CAC CCG
S  R  N  L  G  K  V  G  S  K  C  C  K  H  P>
__b__b__b__b__b__OPTIMIZED HSA __b__b__b__b__b__>

      1400         1410         1420         1430         1440
GAG GCC AAG CGC ATG CCG TGC GCC GAG GAC TAC CTC TCC GTG GTG
E  A  K  R  M  P  C  A  E  D  Y  L  S  V  V>
__b__b__b__b__b__OPTIMIZED HSA __b__b__b__b__b__>

```

```

      1450      1460      1470      1480
CTC AAC CAG CTC TGC GTG CTC CAC GAG AAG ACC CCG GTG AGC GAC
L  N  Q  L  C  V  L  H  E  K  T  P  V  S  D>
__b__b__b__b__b__OPTIMIZED HSA __b__b__b__b__b__>

      1490      1500      1510      1520      1530
CGC GTG ACC AAG TGC TGC ACC GAG AGC CTC GTG AAC CGC CGC CCG
R  V  T  K  C  C  T  E  S  L  V  N  R  R  P>
__b__b__b__b__b__OPTIMIZED HSA __b__b__b__b__b__>

      1540      1550      1560      1570
TGC TTC TCC GCC CTG GAG GTC GAC GAG ACC TAC GTC CCG AAG GAG
C  F  S  A  L  E  V  D  E  T  Y  V  P  K  E>
__b__b__b__b__b__OPTIMIZED HSA __b__b__b__b__b__>

      1580      1590      1600      1610      1620
TTC AAC GCC GAG ACC TTC ACC TTC CAC GCC GAC ATC TGC ACC CTC
F  N  A  E  T  F  T  F  H  A  D  I  C  T  L>
__b__b__b__b__b__OPTIMIZED HSA __b__b__b__b__b__>

      1630      1640      1650      1660
TCC GAG AAG GAG CGC CAG ATC AAG AAG CAG ACC GCC CTC GTC GAG
S  E  K  E  R  Q  I  K  K  Q  T  A  L  V  E>
__b__b__b__b__b__OPTIMIZED HSA __b__b__b__b__b__>

      1670      1680      1690      1700      1710
CTC GTG AAG CAC AAG CCG AAG GCC ACC AAG GAG CAG CTC AAG GCC
L  V  K  H  K  P  K  A  T  K  E  Q  L  K  A>
__b__b__b__b__b__OPTIMIZED HSA __b__b__b__b__b__>

      1720      1730      1740      1750
GTG ATG GAC GAC TTC GCC GCC TTC GTG GAG AAG TGC TGC AAG GCC
V  M  D  D  F  A  A  F  V  E  K  C  C  K  A>
__b__b__b__b__b__OPTIMIZED HSA __b__b__b__b__b__>

      1760      1770      1780      1790      1800
GAC GAC AAG GAG ACC TGC TTC GCC GAG GAG GGC AAG AAG CTC GTG
D  D  K  E  T  C  F  A  E  E  G  K  K  L  V>
__b__b__b__b__b__OPTIMIZED HSA __b__b__b__b__b__>

      1810      1820      1830
GCC GCC AGC CAG GCC GCC CTC GGC CTC TGA
A  A  S  Q  A  A  L  G  L  *>
__b__b__OPTIMIZED HSA __b__b__b__>

```

Figure 18. Plasmid map of pAPI504




Figure 19. Plasmid map of pAPI508




Figure 20 Impact of recombinant human lactoferrin on DNA replication of HT29 cells




Figure 21. Cell culture media supplemented with recombinant human lactoferrin expressed in rice grain promotes cell growth and increases the cell number.




Figure 22. Cell culture media supplemented with recombinant human lactoferrin (LacrominTM) expressed in rice grain promotes hybridoma cell growth and increases hybridoma cell number.




Figure 23 Effect of recombinant human serum albumin (rHSA) and plasma-derived human serum albumin (pHSA) on the growth of hybridoma AE1 cells in common medium (DMEM containing reduced 1% FBS) (CM). Cells were gradually adapted to CM with either 1)pHSA 2)nHSA or 3) no HSA and maintained for 10 passages to obtain a stable phenotype. On the 10th passage cells were seeded at 1×10^5 cell/ml on day 0 and cell numbers were counted daily for four days.




Figure 24. Effect of recombinant human serum albumin (rHSA) and plasma-derived human serum albumin (pHSA) on the growth of hybridoma AE1 cells in DMEM/F12 serum-free medium (SFM). Cells were gradually adapted to SFM with either 1) pHSA 2) rHSA or 3) no HSA and maintained for 6 passages to obtain a stable phenotype. On the 7th passage cells were seeded at 1×10^5 cell/ml on day 0 and viable cell numbers were counted daily for 5 days.

